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ABSTRACT 
 
Peanut agglutinin (PNA) is a dietary lectin which accounts for 0.15% of the 
total weight of peanut Arachis hypogaea. PNA is a galactoside-binding protein 
which binds highly specifically to the tumour-associated Thomsen-Friedenreich 
blood group antigen. Previous studies demonstrate that PNA rapidly enters the 
blood circulation after peanut ingestion. PNA interacts with oncofetal TF 
disaccharide on the transmembrane mucin protein MUC1, causing polarization of 
MUC1 and thus reveals functional cell surface adhesion molecules. Therefore, 
circulating PNA has potential effects by inducing cancer cell homotypic and 
heterotypic adhesion, cell survival and migration, thus potentially promoting 
cancer metastasis and resistance to anoikis. In addition, earlier studies from our 
group have shown that a human galactoside-binding galectin-3 also interacts with 
MUC1-TF potentially inducing cancer metastasis from vascular endothelium. It is 
also reported that circulating galectin-3 enhances cytokine secretion from 
endothelial cells, and this interaction is suggested to be responsible for the 
metastasis-promoting effect of galectin-3. This thesis further explores the PNA 
effect on endothelial secretion of metastasis-associated cytokines. The study 
presented here reports that PNA at a concentration similar to that found in the 
sera of people after eating 200g peanuts causes increase of IL-6 and MCP-1 
secretion from both micro-vascular and macro-vascular endothelial cells. The 
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PNA-induced cytokine secretion was found to enhance endothelial expression of 
several cell surface adhesion molecules, leading to increased cancer cell-
endothelial cell adhesion. The increased cytokine secretion is also shown to 
promote endothelial cell adhesion, proliferation and angiogenesis. The molecular 
mechanism of the PNA-induced cytokine secretion is also studied, and two cell 
surface adhesion molecules MCAM and PECAM were identified as major functional 
receptors of PNA. Moreover, siRNA-mediated suppression of MCAM and PECAM 
expression completely abolished the PNA-induced cytokine secretion from 
endothelial cells. This study also investigated the cell signaling involved in the 
potential pro-metastasis effect of PNA.  The results from this study suggested that 
the actions of dietary PNA in cancer patients might have impacts on cancer growth 
and metastasis. 
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ABBREVIATIONS 
 
Akt    Protein Kinase B (PKB) 
ASF    Asialofetuin 
ATP    Adenosine triphosphate 
BCL2    B-cell lymphoma 2 
BRCA1/2   Breast Cancer genes 1 or 2 
bFGF    Basic fibroblast growth factor 
BSA     Bovine serum albumin 
CAMs    Cell adhesion molecules 
CCL2    Chemokine (C-C motif) ligand 2 (MCP-1) 
CCR    C-C motif receptor 
CD146    Melanoma cell adhesion molecule (MCAM) 
CD23    Fc epsilon RII (FcεRII) 
CD31    Platelet endothelial cell adhesion molecule (PECAM) 
CD44    Homing cell adhesion molecule (HCAM) 
CM    Conditioned Medium 
CRC    Colorectal Cancer 
CRDs    Carbohydrate recognition-binding domains 
CTL    C-type lectins 
DMEM    Dulbecco’s modified Eagle’s medium 
DMSO    Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
ECL    Enhanced chemiluminescence 
ECM    Extracellular matrix components 
EDTA    Ethylenediaminetetraacetic acid 
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EGF    Epithelial growth factor 
EGM    Endothelial growth media 
ELISA    Enzyme-linked immunosorbent assay 
FCS    Fetal calf serum 
Gal    Galactose 
Glc    Glucose 
G-CSF    Granulocyte colony-stimulating factor 
GlcNAc   N-acetylglucosamine 
GM-CSF   Granulocyte-macrophage colony-stimulating factor 
HCAM    Homing cell adhesion molecule 
hEGF    Human Epidermal Growth Factor 
HMVEC-Ls   Human micro vascular lung endothelial cells 
HUVEC   Human umbilical vein endothelial cells 
ICAM-1   Intercellular adhesion molecule-1 
Ig-CAM   Immunoglobulin-like Cell Adhesion Molecules 
IgSF    Immunoglobulin superfamily 
IKK    IκB kinase 
IL-6    Interleukin 6 
JAK    Janus kinase 
KSHV    Kaposi’s sarcoma-associated herpesvirus 
MAPK    Mitogen-activated protein kinases 
MCAM    Melanoma Cell Adhesion Molecule 
MCP-1    Chemokine (C-C motif) ligand 2 (CCL2) 
MEK    Mitogen-activated protein kinase 
MHC    Major Histocompatibility Complex 
MIP    Macrophage Inflammatory Proteins 
MMP    Matrix metalloproteinase 
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MMR    Mismatch repair 
MUC1    Membrane-associated sialomucin episialin 
NAC    N-acetylcysteine 
NF-Kappa B   Nuclear factor Kappa B 
NIH    National Institute of Health 
NK    Natural killer cell 
PAGE    Polyacrylamide gel electrophoresis 
PBMC    peripheral blood mononuclear cells 
PECAM   Platelet endothelial cell adhesion molecule 
PNA    Peanut agglutinin 
Poly-HEMA   Poly-2-hydroxyethyl methacrylate 
RGD    Arginylglycylaspartic acid (Arg-Gly-Asp) 
SDS    Sodium dodecyl sulphate 
SiRNA    Small interfering RNA 
STAT    Signal Transducers and Activators of Transcription 
TEMED   Tetramethylethylenediamine 
TF Thomsen-Friedenreich oncofetal carbohydrate 
antigen (N-acetyl-D-galectosamine linked to protein) 
TNF-α    Tumour necrosis factor-alpha 
TNM The TNM Classification of Malignant tumour (, 
Lymph Nodes, Metastasis) 
cTNM Clinical TNM 
pTNM Pathological testing 
UICC Union International Cancer Control 
UV    Ultraviolet light 
VEGF    Vascular endothelial growth factor 
VCAM-1   Vascular cell adhesion protein 1  
WHO    World Health Organization 
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CHAPTER 1 Introduction 
1.1 Cancer  
1.1.1 General 
The words cancer and carcinoma come from the Latin (cancer) and Greek 
words Karkinos (carcinos) for crab. This was first used by the Greek physician 
Hippocrates investigating the appearance of the cut surface of a removed 
malignant tumour with "veins stretched on all sides as the crab has its feet". [1] In 
addition, he even recorded several types of cancer including breast cancer at 
around 460-370 B.C. but the earliest evidence of cancer is from mummies which 
contained evidence of human bone cancer in ancient Egypt. [2] An ancient 
manuscript, the Papyrus Ebers, described cancer without naming it, and even 
includes the first description of a surgical treatment of breast cancer with a 
tumour removal procedure using cauterization at around 1600BC. [3] The 
theories of cancer have changed over the past two thousand years, along with the 
developing understanding of cancer. [4] 
Cancer is a cluster of diseases and can happen in any part of the body. From 
the data published by the World Health Organization (WHO), 1.7 million people 
die from lung cancer together with trachea and bronchus cancers each year, 
increasing from less than 1 million deaths in 2002, making it the 6th leading cause 
of deaths in the world in 2016. Cancer overall is the 2nd leading cause of death 
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worldwide in 2018. The World Health Organization reports 18.1 million people 
developing cancers and 9.6 million dying from cancer worldwide in 2018. This 
amounts to about 1 in 5 in men and 1 in 6 in women dying from cancers around 
the world. The latest cancer statistics from Cancer Research UK states that 1 in 2 
UK residents will have cancer diagnosed in their lifetimes. The most common 
cancers are lung, breast, colorectal, prostate, skin and stomach cancer, and the lung, 
breast, colorectal, stomach, and liver are the top five causes of cancer death. [5]  
There are over 200 different types of cancer and all start with abnormal 
behaviour in a single cell or group of cells. A normal cell has a controlled cell cycle 
including division, duplication and cell death which regulates cell growth and 
differentiation, invasiveness and apoptosis. [6] It was first suggested by Peter 
Nowell in 1976 that genetic instability is the key to cellular evolution and mutation 
to cancer. [7] The transformation from normal cells to cancer cells involves a 
multistage process. [8] This is determined by the interaction between individual 
genetic factors and external factors which may be physical, chemical or biological. 
[9] When these changes happen in any cell, the cancer cell becomes uncontrollable 
and grows and divides unstoppably. When the cancer cells grow and accumulate 
into a solid tissue, the lump is then called a tumour.  
Genetic abnormalities may lead cancer cells to behave differently from the 
normal cell through many biological functions such as cell proliferation, migration, 
adhesion and survival. It is also shown by microscopy that cancer cells have 
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different shapes from normal cells. [10] Cancers are classified pathologically by 
the tissue origin into five main types, carcinoma, sarcoma, leukaemia, and 
lymphoma and brain/spinal cord cancers. The Cancer Research UK has reported 
that epithelial malignancies account for 85% of cancers in UK. Carcinomas are 
more frequent in adults than in children and this frequency increases with age. [11] 
Carcinomas are also classified according to their organ of origin: eg colorectal 
cancer, breast cancer and lung cancer. In addition, modern genomics studies also 
allow a molecular-based classification system.[12] 
With huge amount of research into treatments for different types of cancer, 
the death rate of cancer has declined over the past two decades. It has been 
reported that improved cancer treatment and especially screening has contributed 
greatly to this decreased death rate for cancers such as colorectal, breast and 
cervical cancer.  [13]  
Staging is an important and essential step in preparation for further 
treatment of any types of cancer. It was first proposed by Pierre Denoix between 
1943 and 1952 that a Tumour, Node, Metastasis (TNM) staging system should be 
used for categorization of malignant tumours. [14] This TNM classification is 
continuously edited by the Union International Cancer Control (UICC) with clinical 
data collected worldwide.  The TNM classification describes a cancer as T1-T4 for 
increasing size of primary tumour, N1-N3 for increasing spread to regional lymph 
nodes and M0 or M1 for absence or presence of distant metastasis. [15] 
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Additionally, TNM is separated into two types of classification, the clinical TNM 
(cTNM) which refers to cancer staging before treatment, and pathological TNM 
(pTNM) which refers to cancer staging after therapy or after pathological testing 
in the laboratory. It is also common to combine the TNM results into four stages 
such as stages I, II, III and IV. [1] For example, carcinoma in situ is grouped to Stage 
I cancer, and Stage II describes an invading tumour which might spread to regional 
lymph nodes. Progression through grades 1-4 is associated with increasing 
abnormality of tumour cells comparing to normal cells. [16] After staging, cancer 
treatment is selected depending on the individual specific cancer type. Until 
recently, the main treatments for cancer have been surgery and radiotherapy. 
Modern cancer treatment with high technology now involves many methods such 
as chemotherapy, hormone therapy and, increasingly, gene therapy and 
immunotherapy. Above all, the choice of cancer treatment depends on good 
communication between the medical team and the cancer patient. [2, 17] 
 
1.1.2 Genetics and Physiology 
Cancer is a genetic disease characterized by the emergence of deranged 
versions of normal cells, born out of aberrant molecular biology. Normal cells have 
a nucleus containing chromosomes which in total contain about 25,000 genes. A 
gene is a segment of deoxyribonucleic acid (DNA) that codes for an individual 
protein, and these proteins then control and modulate cell activities. Genes contain 
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unique messages that relate to cell types, functions, division and death. [8, 10, 18] 
Tumour development involves both promotion and escape from restraining forces. 
Uncontrolled cell-cycle progression is produced by this interaction. [19] Research 
into rare autosomal dominant monogenic cancer syndromes has greatly helped 
the understanding of cancer biology. The familial cancers may result from rare 
germline mutations in highly penetrant genes such as the BRCA1/2 mutation in 
breast cancer. [20] Alternatively, cancers result from acquired mutation, so-called 
sporadic cancer, and express few or no germline mutations. [21] Earlier studies 
have shown sporadic cancers such as breast cancer are influenced by 
environmental factors including diet and tobacco, and are associated with various 
genetic polymorphisms. [22] Chronic inflammation also plays an important role in 
the development of many carcinomas and this can involve infectious agents such 
as Helicobacter pylori in stomach cancer. [23] 
Cancer is a complicated disease arising by a multistep process involving 
clonal expansion, genetic alteration and clonal selection with clone evolution 
within tissue ecosystems that follow the proven Darwinian evolution theory. [24] 
The cancer clone evolution involves selective sub-clone expansion. Darwinian 
natural selection can be advantageous to cancer cells, empowering clone 
expansion with characteristics of extensive proliferation, resistance to apoptosis, 
immortality, angiogenesis and metastasis. [25] It was first suggested by Douglas 
Hanahan and Robert A. Weinberg that there are six hallmarks of cancer. [26] These 
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six common biological capabilities involve tumour cell sustaining proliferative 
signals, irrespective of growth suppressors, resistance to apoptosis, unrestricted 
replicative potential (immortality), sustained angiogenesis and ability to invade 
surrounding tissue and metastasize. In addition, recent studies demonstrate the 
Warburg effect in which cancer cells favour metabolism of glycolysis with 
increased ATP production. This and tumour-promoting inflammation have been 
recorded as the seventh and eighth hallmark features. [27, 28]  
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1.2 Cancer Metastasis 
1.2.1 General 
The mortality of cancer is usually associated with cancer metastasis.  
Metastasis is the transport of cancer cells detached from the original tumour site 
to other parts of the body and formation of secondary tumours. [29] Metastasis is 
a multistep interrelated process. Through mutation, de-differentiated cancer cells 
are maintained by specific survival factors that prevent cancer cell death by 
apoptosis (programmed cell death). [30] Metastases are initiated through the 
overgrowth of cancer cells into a proliferative state, forming a tumour. Then, blood 
vessels form and penetrate the tumour. The tumour cells then break into the blood 
vessel and invade the circulation. [31] Until now, it has been generally considered 
that if tumour cells do not spread, the cancer can be cured. In fact, 99% of invading 
tumour cells will be destroyed by specific apoptotic processes, often involving the 
immune system. However, a small proportion of tumour cells invade the 
circulation, form tumour emboli via cell-cell attraction, and adhere to vessel walls, 
followed by extravasation.[32] In the process of metastasis, many glycoproteins 
play an important role in tumour cell survival in the circulation and cancer cell 
homo- and heterotypic adhesion. (Figure 1.2.1[29, 33, 34]) 
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Figure 1.2.1: Major steps of cancer metastasis. (Adapted from Fidler et al  
[34]) 
Metastasis accounts for around 90% of cancer mortality and has given 
cancer its reputation as an incurable disease.[35] However, the survival rate of 
cancer has been rising dramatically in the past decade because of advances in early 
diagnosis and cancer growth inhibition. [36] Cancer survival rates vary according 
to the type of cancer, stage of cancer, treatment given and age groups. [5, 37-39] 
Metastasis is a complex progress that involves detachment, migration, 
invasion and adhesion. [40] During angiogenesis, human endothelial progenitor 
cells are generated from both blood and bone marrow and differentiate into 
endothelial cells with functions in cell proliferation, tubulogenesis and 
neovascularization.[41, 42] Cell adhesion including cell-cell adhesion, and 
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adhesion to extracellular matrix (ECM) are important. [43] Normally, cells are kept 
within their defined boundary through cell adhesion which helps maintain their 
stability. In cancer metastasis, dysfunction of cell adhesion allows tumour cells to 
disseminate from their primary site to different locations through the circulatory 
system. [44] Cell adhesion is also an essential part of cell proliferation and survival 
pathways. Cancer adhesion molecules can be mainly divided into two groups: the 
calcium-dependent group including cadherin, integrin or selectins, and the 
calcium-independent group including members of the immunoglobulin 
superfamily and a homing cell adhesion molecule (HCAM) known as CD44. [45] 
The calcium-dependent cadherins include more than 100 members and are 
responsible for different locations like the E-cadherins at the surface of epithelial 
cell and the N-cadherin expressed in neuron differentiation. [46] Another major 
group of cell surface proteins is the immunoglobulin superfamily (IgSF) cell 
adhesion molecules known as Ig-CAM, and are characterized by their shared 
extracellular domains with immunoglobulins. Ig-CAM are calcium-independent 
transmembrane glycoproteins, and only have one Ig-like domain at the N-terminal 
which interacts with other Ig-like domains, integrins and carbohydrates. [45] The 
Ig-CAM can be classified into three classes: members with only a Ig-like domain; 
members with an Ig-like domain and at the other terminus an extracellular 
domain; members with an Ig-like domain and motifs. [47] The second group with 
C-terminal intracellular domains usually activate the extracellular interaction 
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within cytoskeletal or adaptor proteins, and can lead to cell signaling which might 
lead to tumour genesis. [48] It is also suggested that IgSFs can be used as 
biomarkers for cancer metastasis progression. For example, the melanoma cell 
adhesion molecule (MCAM), also known as CD146, is a novel prognostic biomarker 
for melanoma and breast cancer that also affects tumour cell adhesion and 
angiogenesis. [49] MCAM is highly expressed in the endothelial adherent junction, 
and affects blood vessel growth thus promoting neoplastic progression from 
benign to malignant states. [50] Another member of the IgSF, platelet endothelial 
CAM (PECAM), is also expressed in endothelial cell and hematopoietic cells. Recent 
studies suggested that soluble PECAM can be used in the diagnosis of late-stage 
metastatic progression related to its effect in regulation of endothelial cell 
adhesion and migration. [40]  
 
1.2.2 Inflammation and Cancer metastasis 
In the tumour microenvironment, inflammation can cause infiltration by 
innate immune cells such as macrophages, dendritic cells and myeloid-derived 
suppressor cells. It is also found that cancer-associated fibroblasts which mediate 
the tumour-induced inflammation, produce cytokines, chemokines and growth 
factors which as a result assist tumorigenesis by enhancing cancer cell 
angiogenesis, proliferation and invasion. [51] In the past decades, the study of 
interaction between inflammation and tumorigenesis has produced much 
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interesting evidence including genetic, pharmacological and epidemiological 
aspects. [52] The relationship between inflammation and cancer metastasis is now 
well established.  Inflammation has an effect on tumour development's every 
aspect and might in a similar way influence cancer therapies' efficacy. [53] For 
example, inflammation is shown to take part in the pathways that lead to sporadic 
colorectal cancer (CRC). The mechanisms of cancer development mediated by 
inflammation remain unknown, and might vary in different forms of colon cancer. 
[54]  Moreover, the function of cytokines, immune cells and other immune 
receptors has been explored by recent studies in colorectal tumorigenesis, and is 
involved in colorectal carcinoma initiation and metastasis. One of the most 
important risk factors in developing colorectal cancer is inflammatory bowel 
disease. [55] Anti-inflammatory drugs like anti-IL-6 antibody, STAT3 and NF-kB 
inhibitors, may potentially downsize the CRC risk, and clinical trials are ongoing. 
[56] However, anti-inflammatory drugs usually target mature myeloid cells and 
lymphoid cells, that won't develop oncogenic mutations. [57] It is suggested that a 
combination of anti-inflammatory therapy with other regular therapies like 
chemo- or radiotherapy, may increase the therapies' efficacy when preventing or 
treating colorectal cancer and colitis-associated cancer. [58-60] 
Inflammation also contributes in the cancer microenvironment directly 
with a multifunctional effect on cancer cell proliferation and migration by 
secreting metastasis-provoking cytokines. It is known that cytokines including 
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chemokines, interleukins and their receptors are associated with risk for invasion, 
migration and metastasis. [61]  Cytokines are small secreted proteins consisting 
of proteins, peptides and glycoproteins in different parts of human body. The 
molecular weights of most cytokines are around 5-20kDa, and they have 
fundamental functions in signaling pathways. Cytokines are highly inducible and 
play a key role in mediating intercellular signals in the immune system. [62] 
Cytokines can be categorized into various families such as tumour necrosis factors 
(TNF), interleukins, interferons, chemokines, lymphocytes and colony-stimulating 
factors. [63] Recent studies have shown that some of these proteins as well as their 
receptors act as mediators and influence numerous cell activities under 
physiological, pharmacological and pathological conditions. [64] Cytokines 
produced in infection, and inflammation in the tumour microenvironment, play an 
important role in carcinogenesis and metastasis. For example, in breast cancer, 
inflammatory cytokines play an important role in the regulation of angiogenesis 
and consequent prognosis. These pro-angiogenic cytokines have become a 
potential target for cancer therapy. [65] Recent data of pro-inflammatory 
cytokines including IL-1, IL-6 and TGF-β, demonstrate crosslinking between 
inflammation and cancer. [66] 
Inflammation also has an impact on the activation of cytokine receptors 
and intracellular signal pathway by NF-kB which participates in tumour 
progression. [53] NF-kB transcription factors are critical regulators of innate 
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immune responses and inflammation. As a key mediating factor in inflammatory 
signals, NF-kB has received additional consideration as well as its upstream kinase, 
IKK, in associating between inflammation and cancer development. [67] Many 
proinflammatory stimuli activate NF-kB, mostly through IKK-dependent 
phosphorylation and degradation of inhibitor of kB (IkB) proteins. [68] Once 
activated, NF-kB dimers stimulate transcription of genes encoding cytokines, 
growth factors, chemokines, and anti-apoptotic factors. [69, 70] In inflammation, 
NF-kB plays a key role in mediating most effects of activation and organization of 
both innate immune system and the adaptive immune system. [71] NF-kB can be 
found in nearly all cell types in animals and is engaged in cellular development. 
[68, 72] Many structural studies found a structural homology with a Rel homology 
domain on the N-terminus in most NF-kB family members. This structural 
homology with retroviral oncoproteins known as v-Rel, has classified NF-kB as NF-
kB/Rel proteins. Among the NF-kB, there are five members discovered in 
mammals: NF-kB1, NF-kB2, RelA, RelB and c-Rel. [73] NF-kB has two signaling 
pathways, the canonical and the non-canonical pathway. [74] The canonical 
pathway is initiated by binding and inhibited by the IkB kinase secreted from 
cytoplasm, and is predominantly applicable to the p50/RelA and c-Rel dimers. [75, 
76] NF-kB has also been shown to have an essential effect in the activation of many 
proinflammatory cytokines secreted from several different cell types such as 
macrophages, lymphocytes and epithelial cells. Following conditional deletions of 
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IKKb, NF-kB is activated in the tumour microenvironment, and mediates the 
cytokine secretion, and therefore activates pro-carcinogenic pathways in tumour 
cells. [77] When NF-kB dimers are activated, numerous gene transcription of 
encoding cytokines including IL-6 and GM-CSF, chemokines including MCP-1 and 
MIP-1, adhesion molecules including ICAM and VAM, and several anti-apoptotic 
factors occurs. [78-81] Recent studies have shown that NF-kB acts as an 
evolutionarily conserved regulator of the genes coding for antimicrobial peptides, 
including beta defensins. [82] Given its function in gene coding molecule 
expression, NF-kB has a significant effect on the adaptive immune response 
involving the major histocompatibility complex (MHC) proteins, costimulatory 
and pro-inflammatory cytokines such as IL-6 and IFN-beta. [83] The activation of 
NF-kB is responsible for the secretion of some chemokines and cytokines which 
participate in lymphocyte migration and maturation 
In the past decade, numerous studies have indicated that pro-inflammatory 
cytokines especially interleukins may stimulate tumour cell growth and survival 
of tumour cells.  Recent studies have demonstrated the important contribution of 
interleukins, especially with their pleiotropic influence on tumour cell 
proliferation and metastasis. Past study on the expression of soluble interleukin-2 
receptor α in nasopharyngeal cancer patients shows significant increase in 
patients with distant metastasis. It is known that IL-6 mediates estrogen synthesis 
and regulate aromatase activity, and promotes breast cancer metastasis. Recent 
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study shows that IL-6 acts as a genetic factor in breast cancer metastasis with a 
single nucleotide polymorphism (SNP) in IL-6. The SNP in IL-6: rs1800795 is 
suggested in monitoring breast cancer patients with distant metastasis.[84](IL-6 
variant is associated with metastasis in breast cancer patients) [85] IL-6 also 
contributes to pro-tumorigenic activity in bone marrow microenvironment 
enhancing bone metastasis, and promotes cancer progression. The effect of IL-6 is 
associated with its multifunctional role in several signaling pathways. 
(Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor 
compartmentalization and turnover enhances TGF-beta1 signaling) It is known 
that cancer progression involves abnormal cell proliferation, invasion and evasion 
from the immune system. Interleukins are well-known as mediators in stimulating 
immune response, and  in relation to tumour growth and metastasis, members of 
the interleukin family such as IL-6 and IL-10 have  different roles in the acute 
phase responses and immune reactions. [86] In vitro studies showed that 
interleukins promote tumour cell growth in many cancer types such as ovarian 
cancer, kidney cancer and skin cancer, via autocrine- and paracrine- dependent 
manners. [87, 88] Moreover, interleukins secreted by immune system cells will 
mediate the activity of immune system and the stage of malignancy. Recent studies 
suggested that interleukins have an impact on the treatment effectiveness and 
cancer survival rates. [89] In the past decades, it has been shown that other 
inflammatory cytokines such as tumour necrosis factor also play an important role 
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in cancer progression. It is reported that transforming growth factor-β (TGF- β) 
act as regulator in tumour cell proliferation and migration in many types of cancer 
such as breast cancer, colon cancer and pancreatic cancer.  In vivo study has shown 
that IL-6 trans-signaling interacts with TGF-β signaling and prevents tumour 
progression and may be a target for cancer therapy. This relationship between 
TGF-β and interleukin-6 (IL-6) shows the importance of cytokine-cytokine 
interaction  in cancer progression. [90]
 
1.2.3 The endothelium and cancer metastasis 
Cancer cell adhesion to the endothelium is an important stage during 
cancer metastasis and it is therefore very important to understand the 
mechanisms that underlie it. [91] The endothelium is a thin layer between 
circulating blood and the vessel wall. It is therefore seen as the last barrier against 
tumour cell extravasation. Previous study using Arg-Gly-Asp (RGD) analogues, has 
shown that they interfere with the interaction between endothelial cells and 
metastatic cancer cells. The RGD peptide is a core sequence found in fibronectin. 
RGDs are ligands for αvβ3 integrin which is overexpressed on the surface of 
angiogenetic endothelial cells and many types of cancer cells. In lung and liver 
cancer, tumour metastasis is inhibited significantly by this analogue polypeptide 
without interfering with tumour cell proliferation. [92, 93] The RGD-αvβ3 integrin 
interaction on endothelial cell surface is therefore relevant to cancer therapy and 
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diagnosis and also has an important role in angiogenesis. Moreover, studies of 
chemotherapy combined with anti-adhesin therapy show a significant reduction 
of tumour metastasis compared to those with chemotherapy alone. [94] It is found 
that interaction of endothelium-cancer metastasis plays a positive effect on 
increased secretion of cell adhesion molecules which has an anti-tumour role in 
immune response, thus also preventing cancer metastasis. [95] Earlier studies 
demonstrated that tumour metastasis is decreased dramatically in B7-transfected 
melanoma cells. Thus, targeting the interaction of endothelial cells and tumour 
cells is a novel strategy in regulation and prevention of cancer metastasis. [96] 
Interaction between endothelium and tumour cells plays an important role in both 
hematogenous and lymphatic dissemination during cancer metastasis. This 
process is activated through complex pathways involving various multifunctional 
cytokines such as E-selectin, VCAM-1 and IgSF. [97, 98] 
Cytokines can be produced by endothelial cells and can also regulate 
endothelial cell functions, and these highly inducible polypeptide mediators act as 
expression signals for leukocytes in various tissues and organs. Inflammatory 
cytokines like interleukin-1 and TNF modulate haemostasis and inflammation and 
potentially affect endothelial cell functions. The pleiotropic IL-1 acts as an effective 
inducer of procoagulant activity and is temporarily expressed in the endothelial 
cell. [99] Recent studies showed that IL-1 and TNF also mediate expression of 
endothelial adhesive molecules such as ICAM-1, and VACM-1. These inducible 
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glycoproteins which belong to the immunoglobulin (Ig) superfamily were found 
greatly increased by IL-1 and TNF and reached peak levels at about 6-8 h. 
Cytokine-mediated inflammatory activation in endothelial cells, induces the 
expression of adhesion molecules involving VCAM-1 and ICAM-1 which has an 
effect on the inflammatory cell adhesion leading to an adhesion cascade. 
Endothelial cells are activated by inflammatory cytokines and contribute in 
leukocyte recruitment which strongly raises the affinity of receptors for ICAM-1 
and VCAM-1. These were found to be influenced by the conformational changes of 
these ligands which are members of integrin family and mediated by its 
cytoplasmic domains of the beta-2 chain. [100] 
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1.3 Lectins and Cancer 
1.3.1 General and structure 
Over the last decade, many studies have illustrated the presence of 
galactoside-binding proteins, especially various galactoside-specific lectins which 
bind to sugar complexes attached to protein and lipids, on the surface of various 
normal cells and tumour cell lines. Increasingly studies have shown that normal 
cells express endogenous galactoside-binding lectins as mediators of cell adhesion, 
such as hepatocytes and Kupffer liver endothelial cells. [101] Since 1988, lectins 
have been studied with a view to drug delivery. [102] The principle of lectin-
mediated drug targeting is simple. As diseased cells, such as cancerous cells, 
express different glycans compared to normal cells, lectins are used as carrier 
molecules that depend on a specific protein-sugar interaction. [103] This concept 
can be applied not only for the gastrointestinal tract but also for other biological 
sites. [104] In recent studies our group has been interested in the interaction 
between galactoside-binding lectins, such as galectin-3 and PNA, and the 
Thomsen-Friedenreich (TF) carbohydrate antigen which is the core 1 structure of 
O-linked mucin type glycans in cancer progression and metastasis.  [105]  
Lectins are multivalent proteins that bind specific carbohydrates which 
may be displayed on the cell surface. Lectins play important roles in cell-cell 
interaction and communication based on their selective recognition of specific 
carbohydrates. Such carbohydrates include simple monosaccharides and 
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structures containing multiple carbohydrates, also called oligosaccharides. [106]  
Both types of carbohydrates are important ligands for lectins on cell surface 
glycoproteins. [107] Lectins were first discovered in 1888 in plants and are 
abundant in many foods. [108] Lectins help regulation of cell adhesion to 
glycoproteins. Many lectins participate in sugar-specific agglutinins in red blood 
cells and so are widely used to identify blood-type specificity. [109] Similar to the 
interaction of antigen and antibody, lectins can be inactivated by specific 
carbohydrate protruding from soluble glycoproteins. Characterization of the 
primary structural homology between animal lectins and plant lectins is not well 
defined, but they all show specific preferential binding to various mono and 
oligosaccharides. [110] It is possible that lectins from animals and plants may be 
coevolutionary. In recent years, lectins have been studied for their primary and 
three-dimensional structure and their biological functions in animal, plants, 
bacteria and viruses. [108] It was noticed that there is no significant sequence 
similarity in lectin families, but they shared high structural similarity. Thus, all 
lectins have specific lectin-carbohydrate binding activity restricted by amino acid 
residues, in the region known as carbohydrate recognition domain (CRD). The CRD 
typically identifies the non-reducing oligosaccharides of glycolipids and cell 
membrane glycoproteins. [111] 
Lectins are characterized into a range of structurally distinct families. 
According to their different functional groups, they are separated into intracellular 
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lectins including P-type, M-type, L-type and the calnexin family; and the 
extracellular lectins involving C-type, R-type, siglecs, selectins and galectins. [112]  
With the help of identification of CRD amino acid sequences, the majority of lectins 
can be categorized into several structural superfamilies. C-type lectins (CTL) have 
a calcium-dependent CRD and are well-established animal lectins. The CTL 
superfamily members use a calcium ion to bind to carbohydrate through 
interaction with OH groups, the calcium also helps connecting the carbohydrate 
and glutamates. [113]  On the other hand, galectins, or the so-called S-type lectins, 
are relatively much less abundant. Galectins are non-glycosylated, Ca2+-
independent proteins and soluble galactose-binding lectins are found both intra- 
and extracellularly. The galectin family bind specifically to β-galactosides, such as 
N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc). [111] Currently, there 
are 15 galectins that have been discovered in animals, and most are also identified 
in humans. Galectins have various functions in cell activities such as cell-cell 
adhesion, inflammation, immune response, angiogenesis, cellular proliferation, 
signalling and survival. [114] Galectin-3 expression changes dramatically with 
neoplastic progression in tumour cells of the head, neck, stomach, thyroid and 
nervous system. Nevertheless, the expression of galectin-3 in cells is also down-
regulated in many cancers such as breast cancer, cervical cancer and uterine 
cancer. [115] In conclusion, modified galectin-3 expression in malignancies may 
affect cancer cell-cell interactions and cancer cell-normal cell interactions, and 
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therefore might have an effect on cancer cell angiogenesis and metastasis. [111]  
Legume lectins, also known as L-type lectins, are found in the seeds of most 
legume plants. They form one of the largest lectin families and are homologous 
carbohydrate binding proteins. Legume lectins can be classified into several types 
occurring to their monosaccharide specificity. (Table 1.3.1) [116] [116] [116] [116] 
[116] Concanavalin A (Con A) is a mannose specific lectin found from Jack bean 
seed, and acts as a T-cell mitogen. Con A was showed to inhibit hepatoma growth 
in mice. In vitro study also showed that Con A inhibits cell growth of breast cancer 
cell and melanoma cells. [117, 118]The galactose/N-acetylgalactosamine specific 
binding lectin PNA, amaranth lectin (ACA) and jacalin are all TF antigen binding 
proteins. ACA and PNA showed increased colon cancer cell growth whilst jacalin 
inhibits colon cancer cell proliferation. In addition, jacalin mediated TNF-α and 
TGF-β secretion by colon homogenates.[119, 120] The N-acetylglucosamine 
specific lectin wheat germ agglutinin (WGA) was also found to bind to many 
different cancer cells such as colon cancer, pancreatic cancer and stomach cancer. 
With its binding in gastric carcinoma, WGA expression has been suggested as a 
useful prognostic indicator in stomach cancer. [121, 122] 
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Table 1.3.1: Plant lectins and their carbohydrate binding specificities 
and ligands. 
 
1.3.2 Glycosylation and Cancer 
Glycosylation is one of the most significant post-translational alterations 
affecting a large field of biological interactions. These include cell-cell, cell-
extracellular matrix interaction, and glycan-protein, glycan-lipid interactions. [128] 
Deficiencies in glycosylation in humans and their associations with disease have 
demonstrated that the mammalian glycobiome contains an impressive range of 
biological information. [129] Glycosylation, as a post-translational alteration, is 
characterized into five categories of glycans: N-linked glycans, O-linked glycans, C-
Lectin Origin 
Carbohydrate 
specificity 
Ligand Reference 
Concanavalin
A (ConA) 
Canavalia 
ensiformis Mannose 
α-D-mannosyl or α-D-
glycosyl residues  [123] 
Jacalin 
(AIL) 
Artocarpus 
integrifolia 
Galactose/N-
acetylgalactosamine 
Galβ1-3GalNAcα1-
Ser/Thr (TF-Antigen) 
[124] 
Peanut 
agglutinin  
(PNA) 
Arachis 
hypogaea 
Galactose/N-
acetylgalactosamine 
Galβ1-3GalNAcα1-
Ser/Thr (TF-Antigen) 
[125] 
Amaranth 
caudatus 
agglutinin 
(ACA)  
Amaranthus 
caudatus Galactose/N-
acetylgalactosamine 
Galβ1-3GalNAcα1-
Ser/Thr (TF-Antigen) 
[126] 
Wheat Germ 
Agglutinin 
(WGA) 
Triticum 
vulgaris 
N-acetylglucosamine 
GlcNAc or NeuNAc (sialic 
acid) 
[127] 
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linked glycans, phosphoglycans and glypiation. [130] Characterizing each glycan's 
biological role, as well as those of glycan-binding proteins including sialic acid-
binding immunoglobulin-type lectins and galectins, has been shown to make 
significant contributions to the cancer field. Each type of glycosylation interacts 
with specific cancer cell activity as well as with the tumour microenvironment. 
Altered epithelial glycosylation has been discovered in precancerous 
adenomatous polyps, inflammation and colonic disease. The O-linked mucin-type 
glycans that are initiated by GalNAc alpha-Ser/Thr are particularly affected. 
Changes include O-glycan shortening, increased sialylation, decreased sulphation 
and enhanced expression of oncofetal glycans including the Thomsen-
Friedenreich antigen. [131] Till now, the mechanism for these glycosylation 
alterations is not well understood. O-glycans in carcinoma cells often carry a core 
1 structure, while normal cells mostly carry O-glycans with the core 3 structure. In 
colon cancer, the GlcNAc-transferase activity is reduced, as a result, the synthesis 
of the core 3 structure becomes reduced. [132] The increased expression in colon 
cancer of high molecular weight splice variants of cell surface glycoprotein CD44 
showing higher expression of unsialylated TF antigen, the PNA receptor, is found. 
[133] 
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Figure 1.3.2: Glycosylation progression (Adapted from Pinho et al [129] ) 
 
Glycosylation is an enzymatic process which results in linkages between 
glycans to proteins, peptides, lipids and other saccharides. (Table 1.3.2) The 
process of glycosylation forms glycoconjugates. According to the nature of their 
non-glycoside part, glycoconjugates are defined as glycoproteins, glycopeptides, 
glycolipids and lipopolysaccharides. Glycoproteins contain multiple 
oligosaccharide chains (glycans) covalently attached to a polypeptide structure. 
Glycosylation includes N-glycosylation, initiated by N-acetylglucosamine to 
asparagine and O-glycosylation, initiated by N-acetylgalactosamine to serine or 
threonine via attachment through nitrogen or oxygen respectively. [129] Recent 
studies have shown that altered glycosylation on the surface of cancer cells may 
act as a cancer biomarker. Quantification of such glycoconjugates in the serum of 
cancer patients has also been used effectively in serological surveillance for cancer 
diagnosis and monitoring. However, the application of these cancer biomarkers is 
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limited due to their wide expression by different types of cancer cells. Moreover 
there are problems with specificity as similar changes can also be found in some 
inflammatory diseases and non-neoplastic conditions. [134] 
Malignant transformation can be associated with various kinds of altered 
cell glycosylation patterns that may affect glycosphingolipids, glycoproteins and 
glycolipids[135] Mechanisms for the altered glycosylation may include altered 
glycosyltransferase activity, altered substrate availability and Golgi 
disarrangement. [136]  
Mucins are epithelial glycoproteins of large molecular weight and can be 
classified into different types with their unique structure and functions. The two 
main classes of mucins are secreted gel-forming mucins (e.g MUC2, MUC5AC) and 
transmembrane mucins (e.g. MUC1, MUC16). [137] The expression of mucins in 
colon cancer are altered. MUC1 overexpression in colon cancer correlates with 
cancer progression, while MUC2 expression is decreased in non-mucinous 
colorectal adenocarcinoma. [138] Intestinal mucins participate in the function of 
mucosal immune system. Mucin O-glycosylation starts in the Golgi when glycan 
(GalNAc) is added on to the hydroxyl domains of amino acid Ser or Thr. This results 
in the formation of GalNAca1-Ser/Thr (Tn). Tn is elongated into four core mucin-
type O-glycans including TF antigen (GalNAc-beta1,3GalNAc-Ser/Thr, core-1). 
These core glycan structures are then varyingly extended by further glycosylation, 
sialylation and sulphation. [139] In colorectal cancer, MUC1 carries much shorter 
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and less branched oligosaccharides in comparison to normal epithelium. [140] 
 
1.3.3 Galectin-3  
Galectin-3 is a member of the galectin family and is a mammalian beta-
galactoside-binding protein. There are 15 galectins expressed in mammals in 
many cell types. Galectins consist of a carbohydrate-recognition domain, 
containing 130-140 amino acids. [141] All of the galectin proteins bind to 
carbohydrates with terminal galactose residues. Galectins are expressed by 
various cell types, particularly epithelial cells, immune cells and endothelial cells. 
[142] Among the 15 proteins, galectins are divided into three groups: proto-type, 
chimera type and tandem-repeat type. Galectin-3 is the only member of the 
chimera type that contains a non-lectin N-terminal region of 120 amino acids 
connected to the only carbohydrate-binding side, which is similar to the proto-
type. [143] However, it can form various polymers with this unique structure. It 
consists of three domains: one carbohydrate binding domain which is also called 
the COOH-terminal domain, a repeated collagen alpha-like sequence and a 
nonlectin NH2-terminal domain which is the action site of serine phosphorylation. 
Ligands bind to the carbohydrate binding sides and galectin-3 polymerization then 
occurs.  [144] Galectin-3 is found in various locations both inside and outside the 
cell. It has various functions depending on its binding ligands. For example, when 
it binds to Bcl-2 in a variety of carcinomas, it prevents apoptosis and cell growth. 
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Circulating galectin-3 is a key factor in tumour cell adhesion and metastasis. 
Previous studies have shown that the expression of galectin-3 is increased under 
cancer conditions, and it is involved in the regulation of cancer cells in blood 
vessels through interacting with the Membrane-associated sialomucin episialin 
(MUC1) protein. Galectin-3 is increased up to 30-fold in the sera of various cancer 
patients. [145, 146]
 
1.3.4 Galectin-3-MUC1 interaction in cancer metastasis 
Metastasis is a multistep processes. This involves progressive growth of  the 
primary tumour, vascularization, invasion, survival in the circulation, adhesion, 
extravasation and finally progressive growth into secondary tumour. [147] 
Galectin-3 plays an important role on the tumour cell survival in the circulation 
and cancer cell homo- and heterotypic adhesion. Recent studies in our laboratory 
have demonstrated that the increased circulation of galectin-3 is an important 
metastasis promoter of cancer cell haematogenous dissemination. This galectin-3 
effect is attributed partly by the galectin-3 interaction with the TF antigen on the 
large transmembrane mucin protein MUC1, which is also overexpressed in cancer 
cells. MUC1 is normally expressed around the surface of epithelial cells and, 
through its large size, blocks access to other cell surface adhesion molecules. [148] 
When circulating galectin-3 binds to the TF antigen of MUC1-mediated cancer cells, 
the smaller adhesion molecules or ligands on the cancer cell surface become 
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exposed as a result of MUC-1 polarization. These can then lead to tumour cell-cell 
aggregation and embolus formation. Secondly, the small adhesion molecules or 
ligands help epithelial tumour cell-vascular endothelial cell adhesion followed by 
cancer cell extravasation and growth into metastasis. (Figure 1.3) In addition, 
cancer cell adhesion and aggregation partly consequent to the galectin-3 
interaction with vascular endothelial cells, also results in secretion of several 
metastasis-promoting cytokines by the endothelial cells. [149] 
 
Figure 1.3: Galectin-3-MUC1 interactions in the sera of patients with 
metastatic cancer. (Adapted from Chen et al [150]) 
 Galectin-3 in the blood circulation binds to TF-antigen carried by the large 
transmembrane glyocoprotein MUC1 that is expressed around the surface of cancer cells, 
and causes MUC1 polarization and thus exposes adhesion receptors on the surface of 
tumour cells. [151] These can then lead to tumour cell-cell aggregation and embolus 
formation. Secondly, interaction between the adhesion molecules and their ligands lead 
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to epithelial tumour cell-vascular endothelial cell adhesion followed by cancer cell 
extravasation and growth into a metastasis. [152] 
 
 
1.3.5 Galectin-3 induces endothelial cytokine secretion 
Many cytokines, in particular proinflammatory cytokines, such as IL-6, are 
well-known for their prometastatic promotion of cancer cell-endothelial cell 
adhesion. A previous study also showed that increased circulation of galectin-3 
induces the secretion of four cytokines: IL-6, granulocyte colony-stimulating factor 
(G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and 
intercellular adhesion molecular 1 (ICAM-1) both in vitro and in vivo. (Figure 1.4, 
[153]) It is shown from previous study that galectin-3 induced secretion of 
cytokines by microvascular endothelial cells (HMVEC-Ls) is essential for galectin-
3-induced adhesion of MUC-1 negative cancer cells to endothelial cells. Galectin-3 
also induces endothelial cell surface adhesion molecule expression and is 
associated with autocrine or paracrine actions of galectin-3-mediated endothelial 
cytokine secretion. These actions are responsible for various important steps of 
the cancer metastasis cascade such as endothelial cell migration and tubule 
formation. In summary, circulating galectin-3 also has a MUC-1 independent action 
on cancer metastasis as a consequence of stimulating secretion of metastasis-
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promoting cytokines.  [153]  
 
Figure 1.4: Galectin-3 induces secretion of IL-6, G-CSF, GM-CSF, and sICAM-1 
from endothelial but not cancer cells. (Adapted from Chen et al [153] 
Galectin-3 induces secretion of IL-6, G-CSF, GM-CSF, and sICAM-1 from endothelial 
but not cancer cells. Cytokine profile in the conditioned medium (CM) of 24-hour 1 μg/ml 
galectin-3 or BSA-treated HMVECs (A) or ACA19- cells (B). Treatment of H galectin-3 (1 
mg/mL) for 24 hours resulted in increased concentrations of 4 cytokines: IL-6 (2.1-fold), 
G-CSF (2.2-fold), GM-CSF (3.2-fold), and sICAM-1 (2.3-fold) in the culture medium, 
whereas treatment of ACA19 cells with galectin-3 had no significant effect on cytokine 
abundances in the culture medium when the cytokine profiles were analyzed using a 
human cytokine assay array. This suggests that galectin-3 enhances cytokine secretion 
from HMVECs but not ACA19 cells. [153] 
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1.4 Peanut Agglutinin 
1.4.1 General and structure 
Peanut agglutinin (PNA) is a common dietary lectin and is derived from the 
peanut, Arachis hypogea. The molecular weight of PNA is about 110 kDa and it is a 
homo-tetrameric protein with four parallel chains each of 27 kDa. [154] PNA 
accounts for 0.15% of the total peanut weight and is highly resistant to 
degradation during cooking or digestion by gastric acid and enzymes in the small 
intestine. [155] Consequently it can be recovered in active form from faeces. 
Moreover, and remarkably, PNA rapidly enters the blood circulation in intact form 
after peanut ingestion. After ingestion of peanuts, intact PNA can be detected at 
5µg/ml in the systemic circulation at 1-hour time point. [156] It presumably gains 
entry by binding to epithelial surface ligands followed by internalisation but the 
exact site and mechanism are unknown. The overall effect of the uptake of intact 
dietary lectins into the circulation might lead to important interactions with 
circulation and cellular glycoproteins and, therefore, affect cell-to-cell adhesion 
and proliferation. [157-159] 
Previous studies have provided considerable epidemiological evidence for 
the role of diet in colorectal cancer causation. Patients who consumed 100g 
peanuts per day for five days were found on rectal biopsy to show considerable 
increase in epithelial proliferation. PNA remains active in roasted peanuts.[160] 
Moreover there is increased expression of TF antigen in hyperplastic and 
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neoplastic colonic epithelial cells in vitro and in vivo. [161] 
PNA is shown to bind to many abnormal glycosylation sites on the tumour 
cell surface leading to homotypic and heterotypic cell adhesion that could 
potentially promote cancer metastasis. [162] In colon cancer, alterations in 
epithelial cell surface carbohydrate expression are common and are significant 
examples of abnormal neo-expression of oncofetal antigens. [163] These changes 
also happen in hyperplasia and malignancy. [161, 164] All these variations can be 
detected by different specific patterns of lectin-ligand binding. Previous study by 
our group has shown that PNA has mitogenic effects on normal colorectal 
epithelium, if low level TF expression is present, and on HT29 colorectal cancer 
cells. In addition, PNA has also been studied in lymphoid and some vascular muscle 
cells showing mitogenic effects. [165] PNA binding to endothelial cells is increased 
in colonic cancer and adenomas, whereas the binding site is concealed by further 
sialylation in healthy individuals. [166] Earlier study from our group has shown 
that PNA enhances both melanoma and colonic cancer cell growth and adhesion 
to endothelial cells, suggesting that PNA could act as a significant promotor in 
cancer metastasis. [167, 168] 
PNA is not the major allergen responsible for peanut allergy. Allergy to peanut  
is usually lifelong and occurs in early age.[169] Peanut allergy is one of the most 
common food allergies and affects 2% of children in the UK. [170] The allergic 
process is initiated with activation of immunoglobulin E involving a series of 
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functional and regulator proteins. Mammalian IgE provides the first barrier 
against pathogens. [171] [172, 173] There are two fundamental receptors for IgE, 
the high-affinity receptor for immunoglobulin E (FcεRI) and the low-affinity 
receptor CD23. [174] In the human body, FcεRI is initially expressed on the cell 
surface of mast cells, basophils, eosinophils, monocytes and Langerhans cells. 
[175-177] The binding site of FcεRI-IgE is located on the Fcε3 domain of IgE, and 
is mediated by cross-linking with galectin-3 acting as a secretory protein through 
their N-glycans. [178] The binding of FcεRI to IgE activates its function and 
degranulates mast cell and basophils which plays an important effect in type I 
allergic reactions. [179] CD23 is a soluble calcium-dependent lectin and is 
expressed by B lymphocytes, monocytes and eosinophils. [180] CD23 acts as the 
promoter in cell growth of B lymphocytes, and synthesis of IgE. [181] The PNA 
which in contrast to the peanut allergenic glycoproteins, Ara h1/2, is considered 
as a minor allergen, is reported to be involved in the Ig-binding complex. [182] 
Moreover, recent studies have showed that PNA-binding is a new marker for 
histiocytes which are specific cellular members of the immune system that 
participate in both immune and non-immune cellular reactions. [183]  
 
1.4.2 PNA binds to the Thomsen-Friedenreich antigen 
Previous studies have provided much epidemiological evidence of diet and 
colorectal cancer causation. [184] Previous studies have shown that lectins like 
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PNA and galectins that bind to cancer cells such as human melanoma may cause 
increased metastasis. [185] Peanut (Arachis hypogaea) agglutinin, shows specific 
binding to beta-D-galactose residues, and has high affinity for the Gal (β1-3) 
GalNAc carbohydrate sequence which is also known as the Thomsen-Friedenreich 
antigen (TF antigen). As previously mentioned, TF antigen is expressed by the 
transmembrane mucin protein MUC1 which is overexpressed on cancer cell 
surface. [186] TF antigen is expressed in up to 90% of human cancers but is rarely 
expressed on healthy adult tissues. The TF disaccharide is a core carbohydrate 
structure of O-linked oligosaccharides on glycoproteins. [187] It is normally 
concealed by glycosylation, sialylation or sulphation in the normal epithelium but 
becomes expressed in pre-malignant and cancerous epithelia in various sites. It  
behaves as an oncofetal antigen, expressed normally in the foetus then 
disappearing to be expressed again in hyperplasia or malignancy. The increased 
expression of TF antigen is one of the commonest glycosylation changes in cancer 
and probably usually results from Golgi disarray resulting in a change in the site 
within the Golgi of expression of the β-galactosyl (l-3)-GalNac-α (2, 3) sialyl 
transferase. This could be a crucial early step in the development of colon cancer. 
[188] In human melanoma the interaction between PNA and TF antigen occurs 
with high affinity and contributes to cell proliferation and differentiation. [165] 
1.4.3 PNA induces cancer cell proliferation 
Previous studies have showed that PNA has mitogenic effects on colon cancer 
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cells, lymphocytes and on vascular smooth muscle cells. PNA at relevant 
concentrations achievable in vivo causes up to 50% increase in colon cell 
proliferation in vitro and, following peanut consumption, there was a similar (41%) 
increase in rectal mucosal proliferation in vivo in humans. Moreover, after 
ingestion of peanuts, there was a strong relationship between faecal 
hemagglutinating activity against TF-expressing desialylated red blood cells and 
rectal mitotic index. [160, 165] In addition, when combined with epithelial growth 
factor (EGF), PNA and EGF caused maximal stimulation of proliferation much 
greater than either agent alone. This indicated that there might be possibilities for 
interactions between dietary lectins and endogenous growth-related peptide 
molecules in the colonic epithelium. [155] The mechanism of PNA-induced 
proliferation is unknown, but the apoptosis-inducing effects are dependent on 
internalization of the lectins. [166]  
 
1.4.4 PNA as biomarker in cancer 
Studies have shown that the effect of PNA on the cell surface is blocked by 
overexpressed sialic acid thus shielding its ligand. PNA agglutinates human 
erythrocytes only when the Neu5Ac on the cell surface of erythrocytes has been 
removed by prior neuraminidase (sialidase) treatment. PNA induced agglutination 
can be used as a marker for red blood cell polyagglutinability.  PNA is also a T cell 
mitogen. [189]    
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Binding between PNA and breast cancer cells is greater than PNA binding 
to normal cells, again due to increased expression of cancer specific TF antigen. 
[190] PNA-binding has been widely studied as a tumour marker for several 
malignant cell types including the bladder tumour cells and hematopoietic cells. 
[191] It has been shown that PNA predominately recognizes the galactosyl (β-1,3) 
N-acetyl-galactosamine (GalNAc) carbohydrate group which is commonly 
expressed as an O-linked glycan by tumour cells. [192] However it can also bind N-
acetyllactosamine (LacNAc, Galβ1–4GlcNAc) with lower affinity than the TF 
antigen. [193] PNA also interacts with the fibronectin isoform HFL-1 and has 
therefore been suggested as a potential marker for diagnosis and detection of 
rheumatic disease. [194] Previous studies have use fluorescein labelled PNA as a 
marker for both B cell and T cell differentiation. [195, 196] Tagged PNA has also 
been used as a chemiluminescence biomarker in breast cancer histochemistry. 
[197]  
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1.5 Diet and Cancer 
1.5.1 Epidemiology 
Demographic studies have shown that the incidence of cancer is modulated 
by various changes in different populations. It is suggested that increased 
prevalence of unhealthy dietary and lifestyle habits are responsible for recent 
increases especially in colorectal cancer. [198] Diet is of great interest for its key 
role in both cause and prevention of cancer and in relation to different cultural 
models between countries. Earlier studies have estimated that diet may account 
for one quarter of risk factors for cancers in western countries, and is second only 
to tobacco for importance in the cause and prevention of cancer development. 
[199] There has been a significant increase in food consumption per person 
worldwide for the last fifty years although some developing countries such as 
Somalia and Rwanda remain at a low calorie consumption level. [200] Besides the 
remarkable improvements of food consumption level globally, the diet-pattern is 
also changed largely between developing and developed countries. For example, 
the consumption of calories from vegetable oil, meat and sugar has increased 
significantly in China during the past fifty years. [201] These diet pattern changes 
together with reduction in physical activities, will affect the nutrition-related non-
communicable diseases especially cancer. The most popular cause of nutrition-
mediated disease is overweight and obesity from having unhealthy dietary habits, 
particularly in the USA and Western European countries. [202]  
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In addition, several rapidly developing counties such as China, Mexico and 
Brazil are changing their traditional diets from grains and vegetables, into high fat 
and sugar meals with easier access to more meat and animal products as a benefit 
of their high rates of economic development. Globally, both developing and 
developed countries are experiencing a rapid change in their nutrition, with their 
various traditional diet cultures affected by the so-called ‘westernised’ diet pattern 
(high fat, sugar and salt). [203] As a consequence, the incidence of many diet-
related diseases such as diabetes and several types of cancer is increasing 
dramatically worldwide. [204]  
 
1.5.2 Diet and cancer development 
It was first suggested in the 1970s that people having diets high in animal 
products might have high rates of cancers. [205] Studies of people migrating from 
one country to another showed that they soon acquired similar cancer rates as 
their new host country. This showed that in addition to genetic factors, 
environmental factors, particularly diet, must play a crucial role in determining 
country to country variations in cancer rates. [199] The dietary pattern of many 
countries changed substantially between the 1950s and 1990s with increased 
consumption of meat, vegetable oil and sugar. In parallel with these changes of 
food consumption, the cancer rates increased significantly in the past four decades. 
For example, in some countries the consumption from animal products has 
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increased ten-fold over forty years, while the incidence rate of colorectal cancer 
increased five-fold. When compared to Japan, people in the UK who consume a 
western diet pattern show a 35% greater incidence rate of colorectal cancer in 
men. [206] 
Cancer risk may also be related to the ingestion of carcinogens as 
components of food. For example, a three-fold increase in cancer amongst people 
who consume bracken fern in Japan. [207] Epidemiological studies have also 
demonstrated the relationship between consumption of broiled food and reduced 
gastric cancer incidence rates in Americans. [208] Recent studies on the 
regulatory effect of consumption of soy isoflavone genistein and blueberry 
polyphenol on mammosphere formation in breast cancer, indicate that some 
dietary factors might also be beneficial and should be considered in further novel 
targeted cancer therapies. [208]  
Many natural components have been reported to have potential in cancer 
chemoprevention and treatment. Natural phytochemicals such as cyanidins and 
genistein from grapes and soy inhibit angiogenesis, have antioxidant effects, and 
also affect cancer cell proliferation by interaction with growth factors. [209] 
Cyanidin, delphinidin, malvidin and pelargonidin are common anthocyanidins. 
Anthocyanidins are the de-glycosylated forms of anthocyanins. Anthocyanins are 
plant-extracted flavonoids and can be found in a range of fruits, seeds and 
vegetables in the forms of intact glycosides.  Both in vitro and in vivo studies have 
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shown anti-cancer activities of anthocyanins. [210] Recent studies using eleven 
anthocyanin-rich plant extracts showed anti-proliferative effects in colon cancer.  
These include decreased cell proliferation by black lentil, sorghum and red grape 
extracts, and the inhibition of tyrosine kinase by two anthocyanins. [211, 212] 
 Nut consumption has also been associated with health and disease. Nut 
consumption has increased significantly along with the concept of balanced diet 
over the past century. Most of the beneficial effects have been claimed for tree nuts 
although some studies have also grouped ground nuts such as peanuts, which are 
legumes, together with tree nuts. Nuts are known to be rich in vitamin, fiber, 
minerals and high concentration of unsaturated fatty acid. Those bioactive 
compounds make nuts a unique healthy dietary plant sources in addition to fruit 
and vegetables. [213]  Most previous studies have focused on their beneficial 
effects on diseases such as cardiovascular disease and type 2 diabetes. Nut 
consumption was reported to be associated with a reduction of all-cause mortality 
risk, the relationship between nut consumption and cancer is also studied 
worldwide. [214]  
Most previous studies have focused on their beneficial effects on diseases 
such as cardiovascular disease and type 2 diabetes. Nut consumption was reported 
to be associated with a reduction of all-cause mortality risk, the relationship 
between nut consumption and cancer is also studied worldwide. [215] This result 
is however different from an epidemiologic study that involved ten European 
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counties and showed no association between nut consumption and colorectal, 
colon and rectal cancer in mixed gender. Further analysis of the subgroups in that 
study showed inverse relationship between colorectal cancer risk and increased 
nut consumption in women. [216] These results indicates that the relationship 
between nut consumption and risk of colon cancer and colorectal cancer. Is 
complicated and further investigation in this area is clearly needed. 
Peanuts are rich in proteins and involved in daily diet across the world. 
Peanut consumption includes the nuts themselves and derivatives such as peanut 
oil, peanut butter. Peanut shells are also rich in functional polyphenol compounds. 
Previous study showed that polyphenolic extract of peanut shell reduced 
epididymal fat and reduced intracellular lipid accumulation and decreased 
cholesterol concentration in rats. Peanuts contain the polyphenol compound 
resveratrol which can  inhibit colon cancer cell proliferation and vascularization.  
The peanut lectin (peanut agglutinin – PNA) binds highly specifically to TF 
antigen. Other plant-based lectins with similar binding specificity include Jacalin 
(JAC) from jackfruit, Agaricus bisporus (ABL) from edible mushroom, Amaranthus 
caudatus (ACA) from amaranth grain, all of which showed to affect cancer 
proliferation in previous studies. They differ however in their receptor specifcities 
- ABL, JAC and ACA but not PNA also bind to sialylated-TF antigen. Whilst AMA has 
a similar proliferative effect to PNA, ABL and JAC inhibit colon cancer cell growth 
in a dose-dependent manner. Immunoblotting analysis suggested a strong binding 
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glycoprotein at 90 kDa by ABL, ACA and PNA but weakly for JAC. [119] 
 The work in this thesis will address the possibility that the peanut lectin, 
PNA, already known to enter the circulation in intact form after peanut ingestion, 
could, by mimicking the effects of the naturally occurring lectin galectin-3 have 
various effects in cancer metastasis. The mechanisms of these effects are also 
explored.  
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CHAPTER 2 Hypothesis and Aims 
2.1 Hypothesis 
PNA in the circulation may mimic the actions of endogenous galectin-3 by 
interaction with cancer cell-associated MUC1 and thus promote cancer cell 
adhesion and aggregation in tumour cell spreading. PNA appearance in the 
circulation may also act similarly to endogenous galectin-3 by interaction with the 
vascular endothelium and enhance endothelial secretion of metastasis-promoting 
cytokines, thus promoting metastasis. 
 
2.2 The aims of this study 
The aims of this study were to investigate the effect of PNA on endothelial 
cell secretion of cytokines, the underlying mechanism and the biological 
consequence in cancer metastasis. 
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CHAPTER 3 Materials and Methods 
3.1 Materials 
All T25/T75 cell culture flasks, 96-/24- ELISA plates, chemicals of 
analytical grade, Asialofetuin, PNA, FITC conjugated PNA and non-enzymatic  cell 
dissociation solution (NECDS) were from Sigma (Poole, UK).  
Calcein (AM) cell labelling solution (C3099) was purchased from 
Invitrogen (Paisly, UK).  
Human G-CSF, GM-CSF, IL-6, ICAM-1 and MCP-1 ELISA kits were purchased 
from Peprotech (London, UK).  
Biotin-conjugated PNA was  purchased from Vector Laboratories Ltd 
(Peterborough,UK).  
Human cytokine array kit (ARY005), human phospho-kinase array kit 
(ARY003b), Recombinant galectin-3 (MAB1154), antibodies against 
CD146/MCAM (MAB932) and CD144/PECAM-1 (BBA7) were purchased from 
R&D Systems (Abingdon, UK).  
Antibodies against AKT (9272), phosph-AKT (Thr308), PRAS (2610), 
phospho-PRAS40 (Thr246), STAT3 (79D7), phosph-PRAS40 (Tyr705) were 
purchased from NEB (UK). 
3.2 Cell Lines 
 Human microvascular lung endothelial cells (HMVEC-Ls) and human 
umbilical vein endothelial cells (HUVECs) were obtained from Lonza (Basel, 
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Switzerland) and cultured in endothelial growth media (EGM)-2 and EGM  (Lonza) 
respectively.  
Human colon cancer cells SW620 with MUC1 expression and MUC-1- 
negative human colon cancer cells HCT116 were obtained from the European Cell 
Culture Collections via the Public Health Laboratory Services (Porton Down, 
Wiltshire, UK) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) and 
McCoy’s 5a medium respectively. 
The MUC1 negative human colon cancer cells HCT29-5F7 was kindly 
provided by Dr. Thecla Lesuffleur (INSERM U560, France) and cultured in DMEM 
medium. 
The MUC1 negative human melanoma A375 cells ACA19- was kindly 
provided by Dr. John Hilkens (Netherlands Cancer Institute) and cultured in 
DMEM medium[217]. 
3.3 Cell Culture Medium 
(1) EGM-2 and EGM bulletkits were purchased from Lonza. Complete 
EGM-2 (500ml/bottle) contains 10ml FBS, 0.2ml hydrocortisone, 2ml hFGF-B, 
0.5ml VEGF, 0.5mll R3-Insulin-like growth factor-1 (R3-IGF-1), 0.5ml ascorbic acid, 
0.5mlhEGF and 0.5 gentamicin Sulfate and Amphotericin-B (GA-1000) and 0.5ml 
heparin. Complete EGM (500ml/bottle) contains 10ml FBS, 0.5ml hydrocortisone, 
25ml L-Glutamine, 1ml EnGs, 0.5ml ascorbic acid, 0.5ml rhEGF, 0.5ml GA-100 and 
0.5ml heparin. The serum-free EGM-2 and EGM use 25ml fetal bovine serum 
albumin (BSA) instead of FBS, and the other supplements remain the same.  
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(2) McCoy’s 5a medium and DMEM were purchased from Sigma (Poole, 
UK).  Complete McCoy’s 5a medium and DMEM contains 10% FCS, 100U/ml 
penicillin, 100µg/ml streptomycin and 2mM glutamine. The serum-free medium 
use 0.5% BSA instead of FCS, and the other supplements remain the same. 
 
3.4 Cell Counting 
Cell samples were prepared to be evenly suspended in the culture medium. 
Cells were loaded 10µl on the hemacytometer slide, and counted under the 
microscope. The number of cells was obtained with the following equation: cell 
density (/ml)= number of cells per grid square x 104. 
  
 
3.5 Cell Passage 
Cells were incubated at 37℃ in the incubator with 5%CO2 95% O2.  All cells 
were grown in T25 flasks with culture medium till reaching 60%-80% confluence. 
The cells were then released with 1ml trypsin (0.5mg/ml) diluted in PBS, and re-
suspended in culture medium. Endothelial cells were then incubated for 2-4 hrs 
and cancer cells for 24 hrs. When most cells were attached on the bottom of cell 
culture flasks, cell medium was changed with fresh medium to avoid cell damage 
from trypsin. Endothelial cells were routinely passage at a 1:3 subculture ratio and 
cancer at 1:6. Endothelial cells were used within six passages and cancer cells 
were used within eighteen passages in all experiments.  
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3.6 Cell Thawing and Plating 
The cell culture medium was warmed for 20 min before use in 37℃ water 
bath. The frozen vials of cells from the liquid nitrogen cell bank were also warmed 
up in the water bath. For cancer cells, cell supernatant was then added to 10ml of 
pre-warmed culture medium, and centrifuged for 4 min at 1000  rpm. The 
supernatant was discarded and cell pellet was re-suspended in 10ml pre-warmed 
culture medium and seeded into T25 flask. For endothelial cells, cell supernatant 
was added directly into T25 cell culture flask to avoid cell damage from 
centrifugation. Cells were then cultured in an incubator with 5%CO2, 95% O2 at 
37℃. The culture medium was changed every four days. 
3.7 Detachment of the Cells with Non-enzymatic Cell Dissociation 
Solution 
The cell culture medium, NECDs were pre-warmed in water bath. Cells with 
80% confluence in T25 flask were rinsed three times with 10ml sterilised PBS, and 
1ml NECDs was added for 5-10 min at 37℃. When most cells had detached from 
the flasks, 10ml pre-warmed culture medium was added and cells were re-
suspended with repeated aspiration using the pipette. The cell suspension was 
then used in cell counting or experiments.  
3.8 Cell Adhesion Assay 
EGM-2 or EGM and trypsin were warmed up 20 min ahead in water bath 
and conditioned medium were prepared together with endothelial cell monolayer 
62 
 
on Day 1. Endothelial cells with 80% confluence were released from T25 flask by 
trypsinization and re-suspended at 2x 106 /ml in pre-warmed EGM-2 or EGM 
medium. The cell suspension was then added 200μl/well to two 95-well plates for 
three hours (one for conditioned medium and the other for endothelial cell 
monolayer). When cells were attached on plates, culture medium was replaced 
with fresh EGM-2 or EGM medium to remove residual trypsin. The cells were then 
cultured in incubator overnight. On Day 2, endothelial cell monolayers were 
formed. For the conditioned medium plate, treatment of 4µg/ml of PNA or BSA in 
the presence of 20µg/ml ASF or antibodies against IL-6/MCP-1 were applied for 
24 hrs. The cell supernatants were collected as conditioned medium on day 3. For 
the cell monolayer plate, endothelial cell monolayer was washed with sterilised 
PBS and conditioned medium were added into each well before assessment of 
cancer cell adhesion on day 3.  
The cancer cells with 80% confluence were washed with PBS and released 
by NECDS on day 3, as a result, the cancer cell surface proteins would remain intact. 
Cells were then re-suspended at 5x106 /ml in serum-free medium in a 15ml tube 
before labeling with 10μl/ml Calcein AM for 30 min at 37℃. Cells were then washed 
with PBS and re-suspended at 1x105/ml with serum-free culture medium. Then 
100μl/well Calcein AM-labled cancer cells were added into the endothelial 
monolayer plate for 1hr at 37℃.  
The cells were gently washed twice with PBS before measuring the endothelial 
cell-associated fluorescence using the TECAN infinite F200 fluorescent microplate 
reader at 485nm excitation /535nm emission. 
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3.9 Electrophoresis and Lectin/Immunoblotting 
Cells with 100% confluence were washed twice with 10ml PBS in T25 flask 
before adding 1ml sodium dodecyl sulfate(SDS)-sample buffer(prepared as 
below). The cells were incubated for 20 min at room temperature and cell lysates 
were collected in a 1.5ml tube and kept in freezer at -20℃. 
Table 3.1 SDS-sample buffer: 
 2 fold 4 fold 
Stacking buffer 2.5ml 0 
Glycerol 1.0ml (20%) 2ml 
Mercaptoethanol 0.5ml (10%) 1ml 
20% SDS 1.0ml (4%) 2ml 
1% Bromophenol blue 50μl 0.1ml 
 
Before running, the casting frames with glass plates were set up, and running 
gel (prepared as below) was added up to 1cm below the bottom green edge of the casting 
frame. Then 80μl saturated butanol was added to cover the gel creating a leveled 
top. After leaving the gel to set for around 40 min, butanol was then discarded. The 
gel was rinsed three times with 2ml ELGA water and the stacking gel was added 
(prepared as below) and comb inserted before leaving to set for around 20 min.  
 
 
Table 3.2 Resolving buffer (1.5M Tris-HCl buffer): 
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 4 fold 
Tris-base 36.3 g 
Deionized water 120ml 
2N HCl to pH 8.8  
Make up to  200ml 
 
Table 3.3 Stacking buffer (0.5M Tris-HCl buffer): 
 4 fold 
Tris-base 12 g 
Deionized water 120ml 
2N HCl to pH 6.8  
Make up to  200ml 
 
Table 3.4 Running gel preparation: 
Separating gel 4% 7.5% 10% 15% 
Deionized water 6ml 4.85ml 4.2ml 2.35ml 
1.5M Tris-HCl resolving 
buffer 
2.5ml 2.5ml 2.5ml 2.5ml 
10% SDS 100μl 100μl 100μl 100μl 
30% acrylamide 1.35ml 2.5ml 3.33ml 5ml 
TEMED 5μl 5μl 5μl 5μl 
10% ammonium 
persulfate (APS) 
65μl 50μl 50μl 50μl 
 
Table 3.5 Stacking gel preparation: 
Stacking gel 3.75% 4.00% 
Deionized water  3.09ml 3.05ml 
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0.5M Tris-HCl stacking buffer 1.25ml 1.25ml 
10% SDS 50μl 50μl 
30% acrylamide 0.625ml 0.665ml 
TEMED 10μl 10μl 
10% ammonium persulfate 65μl 50μl 
 
When the stacking gel had set, the comb was carefully removed and the 
glass plates were removed from the casting frame and placed in the running 
electrode (short plates inwards). The electrode was then placed into running tank  
with 1X running buffer (prepared as below). Samples were heated for 10 min at 
100℃ before loading samples into wells of the running gel. The gel was first run for 
30 minutes at 70V letting samples run through the stacking gel, and then fun for 90 
minutes at 110V till the sample  runs to the bottom of the gel.  
Table 3.6 Running buffer preparation: 
Tris-Base 30.67g 
Glycine 64.04g 
SDS 2.2g 
Make up to 4L 
 
After running, the plates were removed and rinsed with 1X transfer buffer 
to remove SDS. Running gel was removed carefully from the glass plates and 
transfer sandwich prepared as follows: Negative pole (black) - sponge pad - filter 
paper - gel - nitrocellulose membrane - filter paper - sponge pad - positive pole 
(white). Transfer sandwich was placed into transfer electrode in the transfer tank 
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with 1X transfer buffer (prepared as below). Gel was transferred for 60 min at 
110V.  
Table 3.7 Transfer buffer preparation: 
Tris-Base 12.12g 
Glycine 57.65g 
Methanol 800ml 
Make up to 4L 
 
After transferring, the nitrocellulose membrane was carefully removed 
from transfer sandwich and placed into separate universals with blocking buffer 
(1% BSA in 1% Tween-20 in PBS). After blocking the membrane for 30 min at 
room temperature or 4℃ overnight, first antibody diluted in blocking buffer was 
applied to the membrane and incubated on roller for 2hrs at room temperature. 
The blot was washed for 10 min with 10ml washing buffer (1% Tween-20 in PBSA) 
on the roller at room temperature. Blot was washed three times and the secondary 
antibody diluted in blocking buffer was applied for 1hr at room temperature. Blot 
was washed 5 times with 10ml washing buffer on roller for 10 min each. The 
washing buffer was replaced with Supersignal west solution (0.5ml of each 
solution from the kit). The binding on the blot was visualized using the Molecular 
Imager® Gel DocTM  XR system (Bio-Rad). 
3.10 Cell Proliferation Assay 
EGM-2 or EGM medium and trypsin were warmed up for 20 min in water 
bath before use. Conditioned medium was prepared on day 1 as follows: 
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Endothelial cells with 80% confluence were washed and released by 
trypsinization and re-suspended at 2x105/ml with pre-warmed culture medium. 
Cells were then seeded with 2ml/well into the 6-well plates and incubated for 2hrs 
at 37℃ before replacing with fresh culture medium. Cells were incubated overnight at 
37℃. Endothelial cell monolayers formed on day 2, and were treated with 4µg/ml of 
PNA or BSA in the presence of 20µg/ml asialofetuin (ASF) or antibodies against 
IL-6 (5ng/ml) or MCP-1 (40ng/ml) in the incubator for 24hr at 37℃. The 
conditioned medium from each well was collected for future use on day 3. 
Endothelial cells used for assessment of cell proliferation assay with 80% 
confluence were washed and detached with NECDs on day 3. Cells were re-
suspended at 5 x 104/ml with culture medium before application of 200μl/well to 
each well to be used in 96-well plates. The medium in each well was replaced with 
200μl/well of conditioned medium after 1hr incubation. The cells were incubated 
at 37℃ for 24hr for the endothelial cell growth. The endothelial cells were labeled 
with 10μl/ml Calcein AM Cell Labeling Solution at 37℃ for 30 minutes. 
Endothelial cells were washed twice with PBS and the endothelial cell-
associated fluorescence was measured with the TECAN infinite F200 fluorescent 
microplate reader at 485nm excitation /535nm emission. 
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3.11 Sandwich ELISA Assay for Cytokine quantification in Cell 
Culture Supernatants Samples 
EGM-2 or EGM medium and trypsin were warmed 20 min before using in 
water bath. Endothelial cells with 80% confluence were washed and released by 
trpsinization and re-suspended at 1x105/ml with culture medium on day 1. Cell 
suspensions were seeded into 96-well plate and cultured in incubator for 24hrs at 
37℃. Endothelial cell monolayers were formed and treated with a certain 
concentration of PNA or BSA for 24 hr on day 2. The cell supernatant was collected 
and the concentrations of cytokines in the supernatant were analyzed using 
Cytokine ELISA kits on day 3. (Peprotech)  
ELISA half-well 96-plates were coated with 50μl of Cytokine Capture 
Antibody overnight at room temperature on day 2. The plates were washed three 
times with 100μl/well washing buffer (0.05% Tween20 in PBS) and 150μl of 
Reagent Diluent (1% Bovine Serum Albumin (BSA) in PBS, pH 7.2-7.4) was applied 
to each well for a minimum of 1hr as blocking buffer on day3.  The plates were 
washed three times with 100μl/well washing buffer and 50μl of cell supernatant 
collected above was added to the wells. The 8 points’ serial cytokine standard 
dilution were prepared and added 50μl to the wells. The plates were incubated for 
2-4 hrs at room temperature. Then wells were washed three times with 100μl 
washing buffer and 50μl/well of detection antibody were added to the wells 
before incubating for 2-4hrs at room temperature. The plates were washed three 
times with 100μl washing buffer and 50μl Streptavidin-HRP were added to the 
wells and incubated for 20 min at room temperature. The plates were washed 
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three times with 100μl washing buffer before being introduced to 50μl developing 
solution (Sigma FAST OPD tablets were dissolved in 20ml distilled water) for 20 
min at room temperature. When the colour of the wells turned to a yellow/orange 
colour, 25μl 4M sulphuric acid were added to stop the reaction. The cytokine 
concentration-associated optical density (OD) was measured with the TECAN 
infinite F200 microplate reader at 492nm with a reference at 595nm. 
 
3.12 Assessment of Endothelial Cell Surface Adhesion Molecule 
expression by Flow Cytometry 
Endothelial cells with less than 80% confluence were treated with 4µg/ml 
PNA or BSA for 1hr and released by NECDs. Cells were washed with 10ml PBS and 
centrifuged for 5 min at 1000 rpm. Supernatants were discarded and, 5ml 2% 
paraformaldehyde was applied to the cells for 25 min at room temperature. 
Endothelial cells were washed twice with 10ml PBS and centrifuged at 1000  rpm 
to remove the supernatants.  Cells were counted and re-suspended at 1x106/ml 
with PBS and blocked with 5% goat serum on the roller for 30 min at room 
temperature. Supernatants were removed by centrifugation at 1000  rpm for 5 
minutes. Cells were washed and re-suspended at 1x106 in blocking buffer (1% 
goat serum in PBS) before separating into 1.5ml tubes (1ml/tube). Antibodies 
against CD44 (1mg/ml), α5β1 (1mg/ml), α5β3 (1mg/ml), E-selectin (1mg/ml), 
VCAM (1mg/ml) and ICAM (1mg/ml) all in 1:400 dilution with PBS were applied 
to the cell solutions and incubated on the roller for 1 hr at room temperature or 
overnight at 4℃. Cells were then washed twice with PBS and FITC-conjugated 
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secondary antibodies were applied for 1hr at room temperature. Cells were 
washed three times and re-suspended in PBS in 0.5ml/tube. The expression of cell 
surface adhesion molecules was measured through BD FACSAria III and analysed 
by ImageJ.  
Flow cytometry is a useful tool to measure a range of cell characteristics 
including cell size, number, and cell surface receptor binding. The procedure of 
flow cytometry involves several steps. After the cell suspension (10,000 cells per 
sample was used in this study) were injected into the machine, the cells pass 
through the laser excitation beam one by one and the fluorescence from the 
labelled cell surface adhesion molecules were recorded. Flow cytometry results 
were showed in a graph with cell numbers as against (X axis) fluorescent intensity 
(Y-axis).  
 
3.13 Silver staining 
The silver staining was conducted according to the instructions provided 
with the kit (R&D system). Tris-glycine gels (10%) were prepared as described in 
section 3.9. Protein samples from PNA purification assay were separated by SDS-
PAGE in 10% gel. After protein separation by electrophoresis, the gel was fixed in 
40% methanol/10% acetic acid for 30 mins. Then the gel was treated with 
oxidizer reagent for 5 mins and washed three time with deionized water for 5 mins 
each time till all the tallow colour was removed. The gel was then treated with 
silver reagent for 20 mins followed with washing with deionized water for 1 min. 
The gel was immersed in developer solution until protein bands appeared. The 
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reaction was stopped with 5% acetic acid. Gels was photographed using the 
Molecular Imager® Gel DocTM  XR system (Bio-Rad). 
 
3.14 Mass spectrometry analysis 
The Liquid chromatography-mass spectrometry (LC-MS) assay were  
performed by Dr,  Deborah Simpson in the Institute of Integrative Biology with a 
QExactive quadrupole-Orbitrap mass spectrometer coupled to a Dionex Ultimate 
300 RSLC nano-liquid chromatograph. The LC-MS procedure was the same as our 
previous work. [218] 1 μl of the sample was loaded onto a trapping column with 
loading buffer (0.1% Trifluoroacetic acid, 2% acetonitrile in water) for 7 mins at 9 
μl/min flow rate.  Then the trapping column was set in line using an analytical 
column. Peptides from the sample were eluted by a linear gradient of eluent A (0.1% 
formic acid in water) and B (0.1 formic acid in acetonitrile) (96.2% A: 3.8% B to 50% 
A : 50% B over 30 mins) at a low rate of 300 nl/min. The effluent was introduced 
into the ultrasensitive nano-electrospray ionization source in positive ion model. 
The data-dependent mass spectrometry was operated and data were analyzed as 
described in our previous work. The mass spectrometry analysis was conducted by 
Dr. Deborah Simpson in IIB in the University of Liverpool. 
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3.15 Statistics 
Data were analyzed using independent t test, analysis of variance and one-
way ANOVA followed by Bonferroni as appropriate. 
  
73 
 
CHAPTER 4 Investigation of the effect of PNA on the endothelial 
secretion of cytokines 
4.1 Hypothesis and Aim 
4.1.1 Hypothesis 
The hypothesis of this part of the study is that the presence of PNA in the 
circulation after peanut ingestion may like, endogenous TF-binding galectin-3, 
also interact with vascular endothelial cells to promote endothelial secretion of 
cytokines that could promote cancer metastasis.  
4.1.2 Aim 
To assess the effect of PNA on endothelial secretion of metastasis-
promoting cytokines. 
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4.2 Introduction 
PNA is one of the commonest dietary galactoside-binding lectins. PNA 
binds highly specifically to the Thomsen-Friedenreich oncofetal carbohydrate 
(galactose β1, 3N-acetylgalactosamine, TF) antigen, which is expressed by the 
transmembrane mucin protein MUC1. [219] The TF disaccharide is a natural 
ligand of several different lectins and it is the core 1 carbohydrate structure of O-
linked oligosaccharides on glycoproteins. TF antigen is expressed in up to 90% of 
human cancers but is rarely expressed on healthy adult tissues. [220] PNA is a 
tightly globular protein and is highly resistant to degradation during cooking or 
digestion by gastric acid and enzymes in the small intestine and can be recovered 
intact in active form from faeces. Remarkably, PNA can rapidly enter the blood 
circulation as an intact protein after peanut ingestion. After ingestion of peanut, 
intact PNA can be detected at 5µg/ml in systemic circulation at 1-hour time point. 
The mechanism of uptake is uncertain but from its speed of action it seems likely 
that it occurs in the stomach, presumably by internalisation after binding to cell 
surface TF-expressing glycoproteins.  [155, 156] 
Previous study in our group has shown the increased circulation of 
galectin-3 in various cancers and that this binds to the TF disaccharide on MUC1 
on cancer cells and induces MUC1 cell surface polarization. [221] This leads to 
increased cancer cell adhesion to the vascular endothelium and cancer cell-cell 
aggregation for increased tumour cell survival in the circulation. It was also 
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revealed that galectin-3 binding to the TF-disaccharide on MUC1 induces cancer 
cell-endothelial adhesion.  [151] More recently, circulating galectin-3 was found 
to interact with CD146 (MUC18) enhancing endothelial secretion of cytokines IL-
6, G-CSF, GM-CSF and sICAM-1. [149] These cytokines are known to be metastasis-
promoting cytokines that increase tumour cell spreading. This part of the study 
aimed to determine whether PNA can mimic galectin-3 and similarly affect 
endothelial secretion of cytokines.     
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4.3 Methods 
4.3.1 Assessment of the effect of galectin-3 and PNA on cytokine 
secretion by microvascular and macrovascular endothelial cells 
HUVECs and HMVEC-Ls monolayers prepared as above (Chapter 3.5) were 
similarly incubated with 4 µg/ml BSA and 1µg/ml, 2µg/ml of PNA, or 1µg/ml, 
2µg/ml, 4µg/ml and 8µg/ml PNA for 24 hr at 37℃. For time-dependent assay, 
4µg/ml PNA or control 4µg/ml BSA were introduced at 6hr, 12hr, 18hr, 24hr, 30hr, 
36hr and 48hr at 37℃. Culture media were collected and levels of cytokines Il-6 
and MCP-1 were determined by cytokine ELISA as described in section 3.11. 
High-binding 96-well plates were coated with anti-cytokine (IL-6, MCP-1) 
antibody in coating buffer overnight at room temperature. The plates were 
washed with washing buffer and incubated with blocking buffer for 1 hr at room 
temperature. Prepared culture media were introduced to the plates for 2 hrs. 
Meanwhile, for the cytokine standard curve, pre-coated 8 wells were introduced 
with diluted standard cytokine with concentration of 0.03125μg/ml, 0.0625μg/ml, 
0.125μg/ml, 0.25μg/ml, 0.5μg/ml, 1μg/ml and 2μg/ml for 2 hrs. Then specific 
cytokine detecting antibody was treated for 1hr at room temperature. After 
introduction of ExtraAvidin peroxidase (1:10,000 dilutions in blocking buffer) for 
30 minutes, the plates were developed with SigmaFAST OPD and the absorbance 
was immediately read at 492 nm using a microplate reader. Cytokine levels in the 
culture media were calculated from the standard curve for each cytokine run in 
each assessment. 
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4.3.2 Human cytokine array 
HMVECs (1x105 cells/ml) were cultured in 6-well plates pre-coated with 
10 mg/ml poly-HEMA, for 24 hr in order to form a firm monolayer. Then the 
endothelial cells were treated with 4μg/ml PNA or control 4μg/ml BSA for 24 hr 
at 37℃. The culture media were collected and incubated with the pre-coated 
Proteome Profiler array membrane overnight at 2-8℃. These membranes can 
detect the levels of 36 different human cytokines, each in duplicate. The 
concentration of cytokines in the culture medium was analyzed according to the 
manufacturer's instructions. The levels of cytokines in the culture medium 
detected in the arrays were quantified with BioRad Image LabTM software. 
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4.4 Results 
The vasculature in the human body is a very complicated structure. There 
is a heterogeneous population of endothelium from macrovascular and 
microvascular vessels in the human body. Galectin-3 and PNA circulate in human 
body and will adhere to either micro- or macrovascular endothelium. In order to 
mimic the performance of galectin-3 and PNA in the human blood circulation, both 
micro- and macro- vascular endothelial cells were used in this study. 
4.4.1 Investigation of the effect of galectin-3 presence on cytokine 
secretion from HMVEC-Ls 
Galectin-3 enhanced G-CSF secretion into the culture medium in a dose-
responsive way. Galecin-3 at 2µg/ml was 12.52-fold higher, and galectin-3 at 
1µg/ml was 4.35-fold higher than the BSA-treated group (P for both <0.001). 
Similarly, GM-CSF in response to 2µg/ml galctin-3 was 1.96-fold higher than the 
control group with a P value of 0.0003. 
Galectin-3 showed similar dose-responsive stimulation of secretion of IL-6 
at 1µg/ml and 2µg/ml galectin-3 treated groups 1.9- and 3.81- fold higher than 
the control group (P for both <0.001). Similarly, with galectin-3 at 1µg/ml and 
2µg/ml, ICAM-1 levels in the culture medium were 2.04- and 2.44- fold higher than 
the BSA treated group (P<0.001 for both). (Fig 4.4.1)  
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Figure 4.4.1: Galectin-3 induces secretion of G-CSF, GM-CSF, IL-6 and ICAM-
1 from HMVECs 
 After incubation of HMVECs with 1µg/ml BSA, 1µg/ml galectin-3 or 2µg/ml 
galectin-3 for 24 hr, the levels of G-CSF, GM-CSF, IL-6 and ICAM-1 in the culture media 
(CM) were analyzed by ELISA.  The data are from at least 3 independent experiments, 
each in triplicate. Data are expressed as mean value ± SD of triplicate. ***p<0.001. (One-
way ANOVA followed by Bonferroni) 
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4.4.2 Investigation of the effect of galectin-3 presence on cytokine 
secretion from HUVECs 
Similar dose-responsive cytokine release was demonstrated in response to 
galectin-3 by HUVECs: G-CSF from 2µg/ml galectin-3 treated cells was 28.92-fold 
higher, and 5.86-fold higher in the 1µg/ml group than the BSA-control group 
(P<0.001 and P=0.0013 respectively). A similar dose-response was shown for GM-
CSF: galectin-3 at 1µg/ml and 2µg/ml causing 1.46- and 4.22- fold increase 
compared with control (P=0.0067 and <0.001 respectively), and also for IL-6: 1.8- 
and 4.58- fold higher than the control group (P=0.003 and <0.001 respectively), 
and for ICAM-1: galectin-3 at 1µg/ml and 2µg/ml inducing 2.51- and 4.75- fold 
secretion compared with the BSA treated group (P=0.009 and <0.001). In 
conclusion, the cytokine secretion from galectin-3 treated HUVECs was also dose-
dependent. (Fig 4.4.2) 
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Figure 4.4.2: Galectin-3 induces secretion of G-CSF, GM-CSF, IL-6 and ICAM-
1 from HUVECs   
After incubation of HUVECs with 1µg/ml BSA, 1µg/ml galectin-3 or 2µg/ml 
galectin-3 for 24 hr, the levels of G-CSF, GM-CSF, IL-6 and ICAM-1 in the culture media 
(CM) were analyzed by ELISA.  The data are from at least 3 independent experiments, 
each in triplicate. Data are expressed as mean value ± SD of triplicate. *P<0.05, **P<0.01, 
***p<0.001. (One-way ANOVA followed by Bonferroni) 
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4.4.3 Investigation of the effect of PNA presence on cytokine(s) 
secretion in HMVEC-Ls 
When HMVEC-Ls were treated with 4 µg/ml of PNA for 24 hr,, a 
concentration that has been found in the circulation after peanut ingestion, 
cytokine array assay for 36 of the most common human cytokines showed 
increase of two cytokines: Monocyte Chemoattractant Protein-1 (MCP-1)11.66-
fold) and IL-6 (3.9-fold) in the culture media from PNA treated cells in comparison 
to that from the BSA-treated cells (control group). (Fig 4.4.3) 
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Figure 4.4.3: The presence of PNA induces secretion of two cytokines 
secreted from HMVEC-Ls 
The levels of 36 common cytokines in the culture medium from HMVEC-Ls cells 
treated with 4 µg/ml PNA or BSA for 24 hr under suspension were assessed by cytokine 
protein array 
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4.4.4 Investigation of PNA effects on IL-6 and MCP-1 secretion from 
HMVEC-Ls 
To investigate whether the IL-6 and MCP-1 secretions induced by PNA 
were dose-dependent, confluent HMVEC-Ls cell monolayers were treated with 
4µg/ml BSA as control group, and different concentrations of PNA (1, 2, 4 and 8 
µg/ml) for 24hr. Then the level of IL-6 and MCP-1 in the conditional medium were 
determined by individual cytokine ELISA. 
Highly significant dose-response to PNA were seen for both cytokines. With 
PNA 4 µg/ml and 8 µg/ml IL-6 was 4.67- and 5.49- fold higher than the BSA treated 
control ( P for both < 0.001) with lower but still significant (P<0.05) increase at 
the lower concentrations (1µg/ml and 2µg/ml PNA) tested.  Similarly, MCP-1 
showed 3.1 to 13- fold increase with 1µg/ml to 8 µg/ml PNA compared to control 
(P < 0.001). (Fig. 4.4.4) 
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Figure 4.4.4: PNA induces secretion of IL-6 and MCP-1 from human micro-
vascular lung endothelial cells (HMVECs) 
After incubation of HMVECs with 4µg/ml BSA, 1µg/ml PNA, 2µg/ml PNA, 4µg/ml 
PNA,8µg/ml PNA for 24 hr, the levels of IL-6 and MCP-1 in the culture media (CM) were 
analyzed by ELISA.  The data are from at least 3 independent experiments, each in 
triplicate. Data are expressed as mean value ± SD of triplicate. *P<0.05, **P<0.01, 
***p<0.001. (One-way ANOVA followed by Bonferroni) 
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4.4.5 Investigation of PNA effects on IL-6 and MCP-1 secretion from 
HUVECs 
To investigate whether the IL-6 and MCP-1 secretions induced by PNA 
were dose-dependent, confluent HUVEC cell monolayers were treated with 
4µg/ml BSA as control group, and different concentrations of PNA (1, 2, 4 and 8 
µg/ml) for 24hr. Then the level of IL-6 and MCP-1 in the culture medium was 
determined by individual cytokine ELISA. Again, similar dose-response to PNA 
was seen for both cytokines. (Fig 4.4.5)  
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Figure 4.4.5 PNA induces secretion of IL-6 and MCP-1 from HUVEC 
After incubation of HUVECs with 4µg/ml BSA, 1µg/ml PNA, 2µg/ml PNA, 4µg/ml PNA, 
8µg/ml PNA for 24 hr, the levels of IL-6 and MCP-1 in the culture media (CM) were analyzed 
by ELISA.  The data are from at least 3 independent experiments, each in triplicate. Data are 
expressed as mean value ± SD of triplicate. *P<0.05, **P<0.01, ***p<0.001. (One-way ANOVA 
followed by Bonferroni) 
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4.4.6 Investigation of the time-response of PNA effects on IL-6 and 
MCP-1 secretion from HMVEC-Ls 
To investigate whether the IL-6 and MCP-1 secretions induced by PNA 
were time-dependent, confluent HMVEC-Ls cell monolayers were treated with 
4µg/ml BSA as control group, and 4µg/ml PNA for 9 time points (0hr, 6hr, 12hr, 
18hr, 24hr, 30hr, 36hr, 48hr and 72hr). Then the level of IL-6 and MCP-1 in the 
conditional medium were determined by individual cytokine ELISA. PNA at 
4µg/ml induced endothelial secretion of IL-6 and MCP-1 progressively over the 
72-hour time course of the incubation. (Fig 4.4.6)  
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Figure 4.4.6 PNA induces secretion of MCP-1 and IL-6 from HMVEC-Ls 
HMVEC-Ls were treated with 4µg/ml PNA or BSA for various time points, the cultured 
medium was collected and levels of IL-6 and MCP-1 in the culture medium were determined 
by IL-6 and MCP-1 ELISA. The data are from at least 3 independent experiments, each in 
triplicate. Data are expressed as mean value ± SD of triplicates. The PNA-treated cytokine 
secretion was analyzed by One-way ANOVA followed by Bonferroni, with comparison to the 
0 hr time point *P<0.05, **P<0.01, ***p<0.001.  
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4.4.7 Investigation of the time-response of PNA effects on IL-6 and 
MCP-1 secretion from HUVECs 
To investigate whether the IL-6 and MCP-1 secretions induced by PNA from 
HUVECs were also time-dependent, confluent HUVEC cell monolayers were 
treated with 4µg/ml BSA as control group, and 4µg/ml PNA for 9 time points (0hr, 
6hr, 12hr, 18hr, 24hr, 30hr, 36hr, 48hr and 72hr). A similar time course was again 
seen for the cytokine response to PNA as in the microvascular cells. (Fig. 4.4.7) 
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Figure 4.4.7 PNA induces secretion of MCP-1 and IL-6 from HUVECs 
HUVEC were treated with 4µg/ml PNA or BSA for various time points, the cultured 
medium were collected and levels of IL-6 and MCP-1 in the culture medium were determined 
by IL-6 and MCP-1 ELISA. The data are from at least 3 independent experiments, each in 
triplicate. Data are expressed as mean value ± SD of triplicate.*P<0.05, **P<0.01, ***p<0.001. 
(One-way ANOVA followed by Bonferroni) 
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4.5 Discussion 
This study confirms that the galactoside-binding protein galectin-3 
induced secretion of G-CSF, GM-CSF, IL-6 and ICAM-1 in both micro-vascular and 
macro-vascular endothelial cells. It was found that the TF-binding protein PNA at 
concentrations found in the circulation after peanut ingestion induces dose- and 
time-dependent secretion of IL-6 and MCP-1 from both micro-vascular and macro-
vascular blood endothelium in vitro. It is believed that circulating PNA binds to its 
receptor(s) on the surface of endothelial cells, and induces signaling leading to 
increased production of IL-6 and MCP-1. The mechanism of this interaction is 
unclear. It is known that cytokine secretion can be up-regulated following 
interactions with the cell surface protease-activated receptor (PAR1) which is a G 
protein-coupled receptor.  
It is known that inflammatory and immune responses play important roles 
in the cause of malignancy. Changes in the inflammatory microenvironment of 
tumours are also believed to be important in cancer metastasis. [222] Since 1863 
when cancer initiation was first reported to occur at sites of chronic inflammation, 
the relationship between inflammation, immune system and cancer is a major part 
in the understanding of cancer development. [223] It is postulated that tumour 
cells interact with various cytokines of the immune system such as chemokines 
and interleukins, in the promotion of metastasis. [224] Previous studies have 
proposed for example that IL-6 is a critical regulator in tumorigenesis and 
metastasis. [225] In this study, both of the two Thomsen-Friedenreich antigen-
specific proteins, galectin-3 and PNA, induced the pro-inflammatory cytokine IL-
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6. In addition, PNA also induced endothelial secretion of MCP-1 which is a 
chemoattractant cytokine.  
Human IL-6 is a glycosylated protein which is around 21-26 kDa with 212 
amino acids. [226] It is a multifunctional cytokine that is secreted, particularly by 
macrophages, in inflammatory, immune responses and infectious disease. 
Pathogen-associated molecular patterns (PAMPs) activate Toll-like receptors 
(TLRs) causing intracellular signaling which induces the production of different 
inflammatory cytokines on the cell surface and intracellular compartments. [227] 
IL-6 was first discovered as a B cell differentiation factor which induces the 
maturation of B cells into antibody-producing cells. [228] Besides its role in 
immune regulation, it plays an important role in the maintenance of hepatocytes, 
haematopoietic progenitor cells, the skeleton, the placenta, the cardiovascular 
system and the endocrine as well as nervous system. In addition, IL-6 is found to 
promote the expansion of progenitor cells by stimulating cells from the resting 
stage to enter the GI phase. [229] IL-6 also supports various physiological 
functions by acting as a hepatocyte stimulatory factor and by inducing acute-phase 
protein synthesis. [230] It is also known to stimulate osteoclast formation, induce 
bone resorption and is responsible for neural differentiation. [231] Thus, IL-6 is 
an important inflammatory cytokine with numerous functions on almost all the 
immune cells. [232] It plays an important role in regulating chronic inflammation, 
and thus mediates the tumour microenvironment and cancer cell growth. [233] 
Recent studies have shown that IL-6 production is correlated with cancer 
development and metastasis so IL-6 blockade has been evaluated for cancer 
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treatment. [226] IL-6 blockade has also been  used in recent novel treatment for 
various diseases such as rheumatoid arthritis, autoimmune diseases, chronic 
inflammatory diseases and especially many types of cancer including myeloma, 
pancreatic, cervical and colon cancers. [234] It is found that there is a particularly 
high level of IL-6 in the serum of multiple myeloma patients. Additionally, IL-6 acts 
as a major inhibitor of plasma cell apoptosis and is a significant cytokine in 
paracrine tumour-associated cell growth in multiple myeloma. [235] IL-6 is also 
seen as a potential immunomodulatory target in immunotherapy of pancreatic 
cancer. [236] IL-6 is overexpressed in the microenvironment of cervical cancer 
where it has a positive influence on the tumour angiogenesis and thus is beneficial 
to cervical cancer development. [237] In the most common and lethal 
gynaecological malignancy, ovarian cancer cells produce IL-6/IL-6R signalling 
which has an important impact on the ovarian tumour microenvironment. [238] 
In addition, IL-6 is also overexpressed in gastric cancer where it plays a similar 
effect by inducing angiogenesis and metastasis. It is suggested that increased 
plasma IL-6 can be used as a predictor in metastasis of gastric cancer. [239] Earlier 
data demonstrated that IL-6 stimulates cancer cell proliferation of colorectal 
cancer. [240] In conclusion, the multifunctional cytokine IL-6 secreted by the 
malignant tumours and inflammatory tissues, has a significant stimulatory effect 
on cancer cell growth and angiogenesis of many cancer types. Furthermore, 
previous studies in many cancer types, show that IL-6 secreted by human 
endothelial cells stimulates tumour cell growth and induces cell apoptosis. [241] 
MCP-1 is a monomeric polypeptide protein which is about 13kDa with 76 
amino acids. MCP-1 acts as a regulatory chemokine in infiltration and migration of 
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macrophages and monocytes, and is thought to be involved in many diseases such 
as cardiovascular disease, atherosclerosis, inflammatory bowel disease and also 
cancer. [242] Mice genetically lacking the receptor for MCP-1, show a significant 
decrease in arterial lipid deposition in an atheroma model. [243] It seems that 
MCP-1 has an important role in atherosclerosis through helping fat-laden 
monocytes transfer to the sub-endothelium. [244] Augmented plasma level of 
MCP-1 that follows coronary's balloon angioplasty arteries anticipates early 
restenosis. [245] A polymorphism in MCP-1 inducer has been shown to be related 
to a raised risk of coronary artery disease[246] and MCP-1 is over expressed from 
macrophage-rich atherosclerotic plaques in primates and humans. [247] 
Moreover, oxidized low-density lipoproteins, promote MCP-1 secretion by smooth 
muscle vascular cells. [248] MCP-1 can be viewed as a potential molecular 
connection between recruitment of foam cells and oxidized lipoproteins to the 
blood vessel wall.  
MCP-1's overexpression in tissues results in a localized infiltration of 
macrophages and monocytes. [249] Thus experimental and clinical inflammatory 
bowel diseases show upregulation of MCP-1 in mucosal tissues. [250] In addition, 
previous studies show a comparable distribution of MCP-1 secretion from 
macrophages, vascular muscle and endothelium. [251] Drug therapy with the 
MCP-1 inhibitor bindarit has been shown to ameliorate trinitrobenzene sulfonic 
acid-mediated colitis in mice. [252] 
MCP-1 and its receptors are found in most tumours and it participates in 
many host activities which impact on cancer development. [253] MCP-1 has 
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significant effects on tumour infiltration by macrophages and on angiogenesis and 
progression. MCP-1 directly mediates endothelial cell angiogenesis both in vitro 
and in vivo. [254] Immunohistochemistry results also showed high expression of 
MCP-1 in breast cancer cells, and proposed to have significant effect in 
macrophage recruitment and matrix metalloproteinases (MMPs) activation. [255] 
The serum levels of MCP-1 from primary ovarian cancer and recurrent ovarian 
cancer, is significantly higher than healthy women. It is suggested that MCP-1 acts 
both as a mediator of cancer cell growth and also of tumour-associated 
macrophage infiltration. [256] MCP-1 is also overexpressed in ovarian cancer 
xenografts from nude mice. [257] It is also suggested that MCP-1 can be used as 
prognostic marker in pancreatic cancer and has functional effect in tumour 
macrophage infiltration and tumour proliferation. [258] Recent studies using 
human gastric cancer cell line TMK-1, MCP-1 transfectants show that is has an 
important role in tumorigenicity leading to increased lymph node metastasis and 
also macrophage recruitment leading to cancer cell angiogenesis. [259] MCP-1 is 
also over-expressed in prostate cancer where it has functional effects on 
proliferation and invasion. [260] Serum MCP-1 is affected by diet -  significantly 
higher in individuals taking a high-fat diet than either high-carbohydrate diet or  
control diet and this is thought to be relevant to prostate cancer development via 
activation of MCP-1/CCR2/Akt signalling. [261] 
Given the various actions of IL-6 and MCP-1 in promoting metastasis, the 
increased secretion of IL-6 and MCP-1 from vascular endothelium in response to 
PNA could have an important impact on metastasis in cancer patients. It is also 
with great interest to study other plant lectins like jacalin which is also specific to 
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the TF-antigen, to see whether they will have influence on cytokine secretion from 
endothelial cells. Recent studies have looked into the interaction between jacalin 
and the macrophage surface, and found induced expression of five cytokines 
including IL-6 secretion induced in a dose-dependent manner. Also the 
mechanism of the increased cytokine secretion by PNA-stimulated endothelial 
cells remains unknown. It is suggested to study the intracellular cytokine 
signalling pathway and possible cell surface receptor(s) which might be 
responsible for the up-regulated cytokine expression.  
In this study, we used both micro- and macro vascular endothelial cells to 
study the role of galectin-3 and PNA in blood circulation. The interior surface of 
blood vessels is a monolayer of endothelial cells - the endothelium. The 
endothelium is an important barrier and participates in inflammatory signalling 
pathways in the process of cancer metastasis especially extravasation. 
Microvascular endothelial cells (such as HMVEC-Ls) are found in small vessels 
such as the capillaries and macrovascular endothelial cells (such as HUVEC) are 
typically derived experimentally from the umbilical vein. HUVECs are commonly 
used in cell culture because of their stability, but HMVECs are more sensitive and 
show higher cell-cell variability. It is suggested that with their quick respond to 
pathology-related tumour microenvironmental alterations, HMVECs should also 
be selected to study cancer cell-related cell activities.  
There has so far been little study of the impact of diet on metastasis 
although there are many studies linking dietary habits to cancer causation. There 
is incomplete evidence on how single nutrients, combinations of nutrients, over 
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nutrition, and energy imbalance, or the amount and distribution of body fat at 
particular stages of life, can influence risk for specific caners. Until more is known 
current recommendations for general health are to consume a mostly plant-based 
diet that includes at least five servings of vegetables, and fruits each day, to choose 
whole-grain carbohydrate sources over refined sources, and to limit saturated fat, 
alcohol, and excess calories. [262, 263] The possible impact of diet on metastasis 
risk in patients with pre-existing cancer clearly deserves much more attention 
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CHAPTER 5 Investigation of the effects of PNA-induced cytokine 
secretion on cancer and endothelial cell behaviour 
5.1 Hypothesis and Aim 
5.1.1 Hypothesis 
PNA-induced secretion of IL-6 and MCP-1 from the endothelium may affect 
cancer and endothelial cell behaviour relevant to cancer metastasis.  
5.1.2 Aim 
To investigate the effect of PNA-mediated IL-6 and MCP-1 endothelial 
secretion on cancer cell-endothelial adhesion, endothelial cell growth, endothelial 
cell tubule formation and expression of cell surface adhesion molecules. 
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5.2 Introduction 
As shown in the previous chapter, the tumour microenvironment produces 
a mixture of cytokines which may have direct or indirect effects in cancer 
metastasis. In particular, PNA was shown to induce increased secretion of IL-6 and 
MCP-1 from endothelial cells. These two cytokines participate in many cell 
activities such as cell adhesion, growth and migration. Previous studies in our 
group have shown that increased expression of the TF-binding lectin galectin-3 
leads to increased IL-6 secretion that increases cancer cell-endothelial cell 
adhesion by increasing expression of endothelial cell surface adhesion molecules. 
Moreover, patients with metastatic cancer show increased expression of G-CSF, 
sICMA-1 and I-6, all of which are secreted from the endothelium in response to 
galectin-3. [149] 
As a multifunctional pro-inflammatory cytokine, IL-6 shows a key role in 
many metastatic cancer types including breast cancer, prostate cancer, renal 
cancer and colorectal cancer. Clinical studies in untreated metastatic breast cancer 
showed the serum levels of IL-6 were higher in patients with more than one 
metastatic site than those with only one metastasis site. The level of IL-6 was 
higher in patients with liver metastasis, pleural effusion or predominant visceral 
disease. Patients with high serum level of IL-6 had a worse survival rate. [264] In 
renal and cervical cancer, IL-6 stimulates tumour cell growth in vitro. [265, 266] 
Activated Kupffer cells release cytokines including IL-6 in association with 
significant increase of colorectal cancer cell adhesion to both cancer cell and 
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endothelial cells, but the IL-6 alone does not have any effect on cancer cell 
adhesion to endothelial cells. [267] 
As a member of the C-C chemokine family, endothelial MCP-1 promotes 
monocyte adhesion to the endothelium and accelerates arteriolar remodelling. 
[268] MCP-1 has a chemotactic effect on both HUVECs and HMECs that is dose-
dependent. In the same study, MCP-1 was also shown to induce secretion of 
angiogenic factors including epidermal growth factor. Antibody-mediated 
inhibition of MCP-1 in mice implanted with human breast carcinomas led to 
increased survival time. [254] MCP-1 also has angiogenic effects by stimulating 
infiltrating macrophages to produce angiogenic cytokines. This is important since 
inflammatory recruitment of macrophages occurs in many tumours. [269] MCP-1 
also promotes the inflammatory response by inducing cytokines including IL-6 
and cell surface adhesion molecules. [270] 
Studies in the previous chapter showed that the presence of PNA induces 
IL-6 and MCP-1 secretion from vascular endothelial cells. The study presented 
here aimed to investigate the potential impact of IL-6 and MCP-1 secretion 
induced by PNA on cancer and endothelial cell activity and behaviours. In addition, 
in order to clarify the PNA effect, we add a specific PNA inhibitor asialofetuin (ASF) 
in this study. ASF is a multivalent glycoprotein and contains both TF antigen and 
N-acetyllactosamine making it an inhibitor for PNA. In the experiment, ASF bind 
to PNA in the cell supernatant and inhibit PNA binding to endothelial cell. 
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5.3 Methods 
5.3.1 Preparation of conditioned medium 
HUVECs or HMVEC-Ls (1.5x105 cells/ml) were cultured in 96-well plates at 
37°C overnight. When a firm monolayer was formed, 4µg/ml PNA was added to 
two groups (three wells/each), 4µg/ml BSA was added to one group (three wells, 
and 4µg.ml PNA + 20µg/ml ASF to another group (three wells) for 24 hrs at 37°C 
overnight. To one of PNA treated group and one of the BSA treated group (three 
wells), 5ng/ml anti-IL-6 antibody and 40ng/ml anti-MCP-1 antibody were added 
and incubated for 30 min. The conditioned media were then collected. 
 
5.3.2 Assessment of cancer cell-endothelial cell adhesion  
It has previously been shown that PNA-MUC1 interaction has a great 
impact on cancer cell-endothelial cell adhesion by PNA binding to TF on cancer-
associated MUC-1. Both MUC-1 negative cancer cells ACA19- and HCT116 and 
MUC-1 overexpressed cancer cells SW620 HT29-5F7 were used here. ACA19-, 
HCT116, SW620 and HT29-5F7 cancer cells were detached using NECDS (to keep 
cell surface adhesion proteins intact.) After washing with PBS and resuspension 
at 5x106 cells/ml in DMEM, cells were labelled with 10µg/ml Calcein AM for 30 
min at 37°C. Then cells were re-suspended at 1x105 cells/ml with serum-free 
DMEM before application to new plates containing HUVEC monolayer with 
prepared conditioned medium. To one group of PNA-treated conditioned media, 
antibodies against IL-6 (10ng/ml) and MCP-1 (80 ng/ml) were introduced. The 
103 
 
cells were maintained at 37°C for 1 hr. After twice washing with PBS to remove 
unbound cancer cells, the monolayer was lysed with 0.25% SDS. The endothelial 
cell-associated fluorescence was read by the fluorescence microplate reader at 
485nm excitation and 535nm emission. 
 
5.3.3 Assessment of endothelial cell growth 
HUVEC or HMVEC-Ls (5x104 cells/ml) were cultured in 96-well plates at 
37°C for 1hr.  The medium was then replaced with the conditioned medium and 
cultured for 24 hr at 37°C. Endothelial cells were then labelled with 2µl of Calcein 
AM for 30 min at 37°C. After three PBS washes, the endothelial cell-associated 
fluorescence was read using a fluorescence microplate reader at 485nm excitation 
and 535nm emission. 
 
5.3.4 Assessment of endothelial cell tubule formation 
HUVECs were seeded in a T25 tissue culture flask until 80% confluence. 
Phenol red free BD Matrigel matrix was thawed at 2-4℃ overnight in a 
refrigerator. The tips and 96-well plates to be used were also kept in the 
refrigerator overnight. Fifty μl Matrigel were aliquoted into each well of a 96-well 
plate on ice. The plate was incubated at 37℃ for 1 hr to allow gel formation and 
make sure no air bubbles were trapped in the Matrigel.  
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A T25 flask of HUVECs was released with 1ml trypsin and washed with PBS. 
After centrifugation at 1000 rpm for 5 minutes, the cells were re-suspended at a 
concentration of 1x105 cells/ml with conditioned medium and seeded at 100μl per 
well to a 96-well plate for 16-24 hr at 37℃.Tubule formation was recorded using 
a Leica dissecting microscope. Micro-photographs of the whole wells of each 
group were taken and the number of tubules and nodules as well as the length of 
each tubule were measured and recorded. Tubule length and branch points were 
calculated using Image J software. 
 
5.3.5 Assessment of expression of cell surface adhesion molecules by 
flow cytometry 
HMVEC-Ls were treated with conditioned medium for 24hr before they were 
released by NECDs. Cells were then washed and fixed with 1ml 2% 
paraformaldehyde. After fixing, cells were washed again and re-suspended at 
1x106/ml with PBS. Cells were then incubated with 5% goat serum and washed 
again before incubating with antibodies against CD44 (1mg/ml), α5β1 (1mg/ml), 
α5β3 (1mg/ml), E-selectin (1mg/ml), VCAM (1mg/ml) and ICAM (1mg/ml) all in 
1:400 dilution with PBS. Cells were then washed and incubated with FITC-
conjugated secondary antibodies.  Cells were washed and re-suspended in PBS in 
small 0.5ml tubes. The cell surface expression of CD44, α5β1, α5β3, E-selectin, 
VCAM and ICAM was analyzed by BD FACSAria III and analysed by ImageJ.  
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5.4 Results 
Previous studies from our group have shown that interaction between PNA 
and TF antigen carried by MUC1 cause several cell activities involving enhanced 
cell adhesion and proliferation. Therefore, in order to assess the impact of  the 
PNA-MUC1 interaction, the MUC1 negative cancer cell line ACA19- and HCT116 
were used together with  MUC1 positive cancer cell lines SW620 and HT29-5F7. 
In this study, conditioned media is used on same condition (passage, cell number) 
of endothelial cells. It is known that after treating with PNA, endothelial cell 
proliferation will increase. In order to test the effect of PNA-mediated cytokine 
secretion on endothelium, cell supernatant is prepared ahead with PNA treatment, 
and applied on fresh endothelial cell monolayer with same passage and cell 
numbers. This avoids the higher number of endothelial cells in PNA-treated group, 
and other possible element activated by PNA binding to TF antigen on endothelial 
cell surface.  
5.4.1 PNA-induced cytokine secretion increases cancer cell 
heterotypic adhesion with microvascular endothelial cells 
The conditioned medium obtained from PNA-treated HMVEC-Ls increased 
adhesion of ACA19- and HCT116 cells adhesion to HMVEC-Ls monolayers by 
100±13% and 72±10% in comparison to the BSA-treated control group. This PNA-
induced increase of cancer cell adhesion was mostly inhibited by ASF, and partially 
inhibited with the present of combination of antibodies to IL-6 (5ng/ml) and MCP-
1 (40ng/ml). The PNA-pretreated group also induced adhesion of SW620 and 
HT29-5F7 cells to HMVEC-Ls by 129±11% and 141±20% when compared with the 
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control. The PNA-induced cancer cell adhesion was fully inhibited by ASF and 
partially inhibited by IL-6/MCP-1 antibodies. (Fig 5.4.1)  
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Figure 5.4.1: PNA-mediated endothelial cytokine secretion increases 
heterotypic cancer cell adhesion with microvascular endothelial cells (HMVEC-Ls)  
HMVEC-Ls monolayers were prepared with conditioned medium. Cancer cells ACA19-, 
HCT116, SW620 and HT29-5 adhesion to fresh HUVECs with or without a combination of 
neutralizing antibodies against IL-6 (5ng/ml) and MCP-1 (40ng/ml). The data are expressed 
as percentage compared with BSA-treated controls from at least 3 independent experiments, 
each in triplicate. Data are expressed as mean value ± SD of triplicate. *P<0.05, **P<0.01, 
***P<0.001. (One-way ANOVA followed by Bonferroni). 
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5.4.2 PNA-induced cytokine secretion increases cancer cell 
heterotypic adhesion with macrovascular endothelial cells 
The conditioned medium obtained from PNA-treated HUVECs increased 
adhesion of ACA19- and HCT116 cells to HUVEC monolayers by 105±12% and 
94±9% in comparison to the BSA-treated control group. This PNA-induced 
increase of cancer cell adhesion was mostly inhibited by ASF, and partially 
inhibited in the presence of a combination of antibodies to IL-6 and MCP-1. The 
ACA19- and HCT116 cell adhesion assays were repeated six times and each 
experiment in triplicate. The PNA-pretreated group induced SW620 and HT29-
5F7 cell adhesion to HUVECs by 147±26% and 164±26% when compared with 
control. The PNA-induced cancer cell adhesion was fully inhibited by ASF and 
partially inhibited by the combination of antibodies to IL-6 and MCP-1. The SW620 
and HT29-5F7 cell adhesion experiments were repeated five times with each 
experiment in triplicate. (Fig. 5.4.2)  
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Figure 5.4.2: PNA-induced cytokine secretion promotes endothelial cell 
migration. 
Conditioned medium was collected after overnight incubation of HUVECs 
monolayers with 4µg/ml PNA, 4µg/ml BSA, 20µg/ml ASF and a combination of antibodies 
against IL-6 (5ng/ml) and MCP-1 (40ng/ml). Cancer cells ACA19-, HCT116, SW620 and 
HT29-5 adhesion to fresh HUVECs was assessed with or without a combination of 
neutralizing antibodies againstIL-6 (5ng/ml) and MCP-1 (40ng/ml). The data are 
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expressed as percentage compared with BSA-treated controls from five independent 
experiments, each in triplicate. Data are expressed as mean value ± SD of triplicate. 
*P<0.05, **P<0.01, ***p<0.001. (One-way ANOVA followed by Bonferroni). 
5.4.3 PNA-induced cytokine secretion induces endothelial cell growth 
Both microvascular endothelial cells and macrovascular endothelial cells 
were prepared and incubated with conditioned medium mentioned above for 
24hr. Endothelial cell growth was then analysed by calcein AM fluorescence and 
showed an increase in both HMVEC-Ls and HUVECs cell growth by 143±16% and 
166±7% respectively in comparison with the BSA-treated control group. (Fig. 
5.4.3) 
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Figure 5.4.3: PNA-mediated endothelial cytokine secretion induces 
endothelial cell growth 
Both HMVEC-Ls and HUVECs were prepared and incubated with conditioned 
medium for 24 hr. The cell growth was analysed by fluorescent labelling the endothelial 
cells. The data are expressed as percentage compared with BSA-treated controls from 
three independent experiments, each in sextuplicate. Data are expressed as mean value ± 
SD of triplicate. *P<0.05, **P<0.01, ***p<0.001. (One-way ANOVA followed by Bonferroni). 
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5.4.4 PNA-induced endothelial secretion of cytokines promotes 
endothelial cell tube formation (angiogenesis) 
The effect of PNA-induced IL-6 and MCP-1 secretion on angiogenesis was 
assessed by measuring HHUVEC tubule formation. Conditioned medium from the 
PNA (4µg/ml) -treated group increased the total length of endothelial cell tubule 
formation by 125±48% compared to the control group.   ASF is a glycoprotein that 
carries several O- and N-linked glycans including TF and sialyl-TF. It is a very 
known binding ligand of PNA and is used as a competitive binding inhibitor for 
PNA binding to cell surface. The effect of PNA on cytokine secretion was inhibited 
by the presence of ASF and also by the presence of antibodies against IL-6 and 
MCP-1.  These results illustrated that PNA-induced endothelial secretion of IL-6 
and MCP-1 promotes endothelial cell tube formation in angiogenesis. (Fig 5.4.4) 
In this experiment, conditioned medium is also used in order to analyse the effect 
of PNA-mediated cytokine secretion on endothelial cells.   
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Figure 5.4.4: PNA-induced cytokine secretion promotes endothelial tubule 
formation 
HUVECs were seeded on matrix gel with 4µg/ml PNA or BSA in the presence or 
absence of 20µg/ml ASF or 5ng/ml anti-IL-6 antibody and 40ng/ml anti-MCP-1 antibody 
for 24 hr. The cell images were taken (A) and the tubular length was quantified (B). Data 
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are expressed as mean value ± SD of triplicate. *P<0.05, **P<0.01. (One-way ANOVA 
followed by Bonferroni). 
5.4.5 Investigation of the effect of PNA treatment on expression of cell 
surface adhesion molecules by HUVECs 
To gain an insight into the mechanism of the PNA-induced, cytokine-
mediated cell adhesion, we analysed the expression of several common cell 
surface adhesion molecules on HUVECs after treatment of the cells with 
conditional medium. HUVEC cells were treated with PNA (4µg/ml) for 24 hr 
before the expression of endothelial cell surface adhesion molecules 
(Integrinα5β1, Integrinα5β3, CD44, E-selectin, ICAM and VCAM) were analysed by 
flow cytometry. 
It was found that HUVECs treated with PNA (4 µg/ml) for 24 hr increased 
expression of cell surface Integrinα5β1 (29.6%), Integrinα5β3 (33.4%) E-selectin 
(20%), VCAM-1 (45.3%), CD44 (18.6%) and ICAM-1 (13.3%) whereas the 
expression of cell surface CD44 and integrinα5β3 was not affected (n=3). The 
presence of antibodies against IL-6 and MCP-1 caused 79±14% reduction of PNA-
mediated increase of VCAM-1 expression.   
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Figure 5.4.5: PNA induces expression of cell surface Integrinα5β1, Integrinα5β3, 
E-selectin and VCAM but not CD44 and ICAM1 
Fresh HMVEC-Ls were incubated with conditioned medium from 
endothelial cells treated with 4µg/ml PNA (green) or without (red), or anti-IL-
6/MCP-1 antibodies (purple) for 24 hr. The cells were released and probed with 
antibodies against Integrinα5β3, integrinα5β1, VCAM-1, ICAM-1, E-selectin or 
CD44. After application of FITC-conjugated secondary antibody, expression of 
these cell adhesion molecules was analysed by flow cytometry. The Ig G control is 
shown in blue (n=3) 
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5.5 Discussion 
This study shows that PNA-induced secretion of IL-6 and MCP-1 from 
endothelial cells increases cancer cell-endothelial cell adhesion of both MUC1-
negative ACA19-, HCT116 and MUC1-positive SW620, HT29-5F7 cancer cells. 
Growth of both microvascular and macrovascular endothelial cells is also 
promoted by this PNA-mediated cytokine secretion. Additional evidence of 
stimulation of angiogenesis is shown by increased tubule length and branch points. 
PNA-induced cytokine secretion also increases expression of several cell surface 
adhesion molecules integrinαvβ1, integrinαvβ3, E-selectin and VECAM-1, but not 
CD44 and ICAM-1. The PNA-mediated increase of VCAM-1 expression is inhibited 
by the presence of antibodies against MCP-1 and IL-6. Thus, the increase tumour 
cell adhesion to endothelium by PNA is likely attributed by the increased 
expression of the cell surface adhesion molecules through IL-6 and MCP-1. 
Tumour cell adhesion to vascular endothelium and endothelial tubule 
formation are two important steps in cancer metastasis. Metastatic cancer cells 
from renal and lung cancers and melanomas have been shown to have much 
stronger ability to bind homotypically to each other and to form potential tumour 
emboli- or heterotypically to the endothelium in comparison with cancer cells 
with lower metastatic ability. [271-273] We have previously shown that cancer 
cell-endothelial cell adhesion can be promoted by the TF-binding glycoprotein 
galectin-3. [274] Such interactions between cancer cells and the endothelium are 
a crucial step in cancer growth and metastasis. [91] Expression of pro-
inflammatory cytokine IL-8 and Gro-β is induced by the interaction between 
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endothelial cells and invasive cancer cells. [275] In breast cancer it has been 
shown that this cytokine induction can increase endothelial barrier permeability 
and thus helps cancer cell adhesion in metastasis. [276] 
The tube or tubule formation assay is a well-known method for measuring 
angiogenesis which was first used in 1988. [277] Previous studies on 
microvascular endothelial cells have shown that recombinant human IL-8 
increases HUVECs cell growth and tubule formation. The in vivo control of 
angiogenesis is incompletely understood. It is proposed that expression of IL-8 
receptors (CXCR1 and CXCR2) are important. [278] There is also evidence for an 
important role of VEGF in gliomas [279] It is thought that inhibitors of 
angiogenesis may have great potential in cancer treatment although earlier 
enthusiasm has yet to be confirmed by convincing translation into clinical practice. 
[280] Previous studies of angiogenesis inhibitors Anginex, endostatin and TNP-
470 had shown that angiogenesis is reduced by all three inhibitors with shorter 
tubule and fewer branch points. [281] 
IL-6 is a pleiotropic cytokine with tumour-promoting effects. Recent 
studies have proposed that IL-6 and E-cadherin are possible factors important in 
breast cancer metastasis formation. It has been reported that up-regulation of IL-
6 may be involved in the high invasiveness and metastatic capability of oestrogen 
receptor-negative tumours. Further, in patients for whom Microscopic 
polyangiitis (MPA) treatment was effective, the IL-6 level prior to treatment was 
clearly low. [282] Moreover, IL-6 induced kinase pathways have roles in 
regulating pathogenic bone remodeling, inflammation, cell survival, proliferation 
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and pro-tumorigenic effect. Accumulating data indicates that overexpressed IL-6 
in cancer correlates with metastasis to bone. [283] IL-6 is also associated with 
auto and paracrine stimulation of tumour cell proliferation, with the upregulation 
of anti-apoptotic proteins, and with the induction of pro-angiogenic cytokines 
including VEGF. These IL-6-mediated effects are all relevant to cancer metastasis. 
[264] Expression of IL-6 mRNA is increased during ovarian folliculogenesis and 
maternal decidual vascularization, two important independent angiogenic 
processes. This is further evidence that IL-6 has an important role in angiogenesis. 
[284] In vitro studies using vascular tumours in syngenic mice showed that 
inhibition of IL-6 causes decreased endothelial cell proliferation and which could 
be regained, dose-dependently, by addition of recombinant IL-6. [285] Blockage 
of IL-6 results in reductions in tumour burden and metastasis in experiment 
models so humanized blocking antibodies such as tocilizumab against IL-6R, are 
already Food and Drug Administration-approved following clinical trials. 
Delineation of the regulatory mechanisms that promote IL-6 secretion might 
promote the further development of targeted therapies. [286] 
Chemokines and their receptors mediate acute inflammation chemokines, 
induced at sites of inflammation, act as chemotactants providing directional cues 
during the migration of leukocytes to damaged or infected tissues. [287] However, 
elevated expression of chemokines, leading to alterations in chemokine-receptor 
signalling, can contribute to chronic inflammation and malignancy. Cancer cells 
and host stromal cells in the tumour microenvironment including endothelial cells, 
fibroblasts, mesenchymal stem cells and infiltrating leukocytes produce a wide 
range of chemokines that exert numerous biological functions during tumour 
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progression and metastasis. [224] Of these, the C-C chemokine subfamily member, 
MCP-1 together with its cognate receptor CCR2 have been shown to play key roles 
in cancer metastasis by sustaining cancer cell proliferation and survival, 
stimulating cancer cell migration and invasion, and inducing deleterious 
inflammation and angiogenesis. [253] MCP-1 has also been shown to be important 
for the recruitment of monocytes to tumours and to be involved in breast cancer 
development. [288] In vivo studies using metastatic breast cancer cells have 
shown increased secretion of IL-8, VEGF and MCP-1. These high levels of cytokines 
have been shown to contribute to the increased adhesion of breast cancer cells to 
HUVECs. E-selectin plays a large part in this adhesion interaction between tumour 
cell and endothelial cells. [276] Previous studies demonstrate MCP-1 with very 
low concentration, has chemotactic effect on both microvascular and umbilical 
vein endothelial cells. In addition, Matrigel studies have shown that inhibition of 
MCP-1 leads to reduction in endothelial cell angiogenesis. [254] Many breast 
cancers secrete MCP-1, and applying neutralizing anti-MCP-1 antibodies 
suppresses experimental lung metastasis by the human MDA-MB-231 breast 
cancer cells. [255] Furthermore, oestrogen receptor-negative breast cancer cells 
show upregulated surface expression of cadherin, which induces lung metastasis 
through regulation of MCP-1 expression. Thus MCP-1 is a key contributor to lung 
metastasis by breast cancer cells. By contrast, the role played by MCP-1 in breast 
cancer metastasis to bone remains largely unknown. [289] 
It is well-known that cell adhesion molecules have an important role in cell 
activities including proliferation, adhesion, migration and invasion, as well as 
angiogenesis. Our studies show that expression of integrinαvβ1, integrinαvβ3, E-
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selectin, slightly ICAM-1 and VECAM-1 are induced by PNA-induced cytokines 
acting on endothelial cells. These cell surface adhesion molecules from the most 
common four groups were selected in this study. Integrins are transmembrane 
receptors that participate in cell-extracellular matrix adhesion. Previous studies 
showed that integrin αvβ1 is overexpressed in melanoma metastases, and a high 
level of integrin αvβ1 expression in melanoma metastasis patients correlates with 
a low survival rate. [290] Similar to integrin αvβ1, αvβ3 is also upregulated in 
melanoma metastasis and thought to have important role in melanoma 
tumorigenesis. Increased expression of αvβ3 vitronectin receptor during 
melanoma progression modulates collagenase and promotes tumour cell invasion. 
[91, 291] Moreover, integrin αvβ3 also mediates tumour-associated angiogenesis. 
[292] E-selectin also has a key role in the cytokine-induced cancer cell-endothelial 
cell adhesion in several cancer types such as breast cancer and colonic cancer. 
[293, 294] Other soluble adhesion molecules, ICAM-1 and VCAM-1 are also 
expressed highly in both colorectal cancer and breast cancer. These three cell 
surface adhesion molecules all correlate with tumour progression and have been 
shown to enhance cancer cell heterotypic adhesion to endothelial cells and also to 
play a role in host immune anti-tumour defense. [295] High serum level of these 
soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) are reported in both 
colorectal cancer and breast cancer where they correlate with decreased survival. 
[296, 297] 
In conclusion, as tumour cell adhesion to endothelium and endothelial tube 
formation are important steps in metastasis and both are enhanced by PNA-
induced cytokine secretion, the presence of intact PNA in the circulation after 
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peanut consumption may plausibly contribute to metastasis by inducing secretion 
of IL-6 and MCP-1. The mechanism of action is not known, the expression of 
several cell surface adhesion molecules increased by PNA in endothelial cells 
contributes to the PNA-induced cancer cell-endothelial cell adhesion. In this study, 
ASF was not tested in the expression of cell surface adhesion molecules due to lack 
of cells number. It is known that glycoprotein ASF bind to tumour cell surface and 
induced tumour cell homotypic aggregation, the interaction was also mentioned 
as the initial indications of lectin activities on cell surface. While, these is no clear 
evidence of ASF interaction with cell surface adhesion molecules such as 
Integrinα5β1, Integrinα5β3 and E-selectin. It is with great interest to test the 
effect of ASF on endothelial cell surface separately and with PNA in future work. 
[298] In addition, as this study has shown a combination of IL-6 and MCP-1 
secretion by PNA from endothelial cells, individual cytokine effects will need to be 
analysed in future research. A recent study has shown that IL-6 works together 
with MCP-1 causing increased vascular inflammation. During the recruitment of 
monocytes into the adventitia, IL-6 secretion is induced and mediates monocyte 
differentiation. Meanwhile activated macrophages up-regulate MCP-1 secretion 
which invade into the media and help further monocyte recruitment. In that way, 
IL-6 and MCP-1 form a loop that greatly increases vascular inflammation. [299] 
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CHAPTER 6 Identification of the PNA binding receptor and the 
underlying mechanism of PNA-induced cytokine secretion 
6.1 Hypothesis and Aim 
6.1.1 Hypothesis 
The mechanism of the interaction between PNA and endothelial secretion 
of cytokine involves the binding receptor for PNA on cell surface of endothelial 
cells.  
6.1.2 Aim 
To identify the PNA binding receptor on the endothelial cell surface 
responsible for PNA-induced cytokine secretion and to study the molecular 
mechanism of PNA-mediated cytokine secretion 
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6.2 Introduction 
It is likely that PNA-induced cytokine secretion is mediated by an 
interaction with glycans expressed on the endothelial membrane.  PNA is a lectin 
which has been shown to be generally non-toxic to cells.[300] It is known that the 
interaction between lectins and cell surface ligands contributes to lectin 
internalization into various cell types, and induces different cell activities such as 
proliferation [301, 302] PNA is a galactose-binding lectin with high specificity for 
the cell surface TF antigen (β-galactosyl(l-3)-α-N-acetylgalactosamine).[303, 304] 
PNA has important mitogenic effects on various human colon cancer cells.[160, 
219, 305] The mechanism of these effects is unknown, but PNA binds to TF antigen 
expressed on high molecular weight splice variants of the transmembrane 
glycoprotein CD44v6 on colon cancer cells, and this interaction initiates 
phosphorylation of c-Met receptor and therefore activates the p44/p42 MAPK cell 
signaling pathway.[306] PNA also interacts with thymocyte surface glycoproteins 
such as CD8 and CD45, and thus mediates intracellular cell signaling affecting 
development of both mature and immature thymocytes.[307-309]  
Circulating galectin-3 is overexpressed in most types of cancer, and plays 
an important role in cancer development with its effects on promoting cancer cell 
adhesion, migration and metastasis.[221] Studies from our group have shown that 
galectins including galectin-3 and galectin-1 strongly bind to the cell surface 
oncofetal TF antigen which is overexpressed on the tumour-associated 
transmembrane mucin protein MUC1, and increases cancer cell adhesion, 
migration and metastasis.[151, 310] Galectin-3 also interacts with various cell 
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surface N-glycans.[311, 312] Previous study from our group has established that 
circulating galectin-3 induces endothelial secretion of metastasis-promoting 
cytokines. The mechanism of this interaction is related to four cell membrane 
glycoproteins, of which CD146 was found to be the major cell surface receptor for 
galectin-3. [149, 218]  
Studies reported in the previous chapter showed that PNA-induced IL-6 
and MCP-1 secretion plays an important role in cell adhesion, proliferation, 
angiogenesis and expression of cell surface adhesion molecules. The study 
presented here aimed to investigate the molecular mechanism of the PNA-induced 
cytokine secretion. It is known that both galectin-3 and PNA bind to TF antigen on 
endothelial cell surface. It is interestig to study whether they have the same 
binding site or not. In this study, a flow cytometry study and cell adhesion assay 
were performed to observe if galectin-3 and PNA have the same receptors on cell 
surface. Then cytokine secretion ELISA assay was done to analyse their 
relationship in cytokine secretion. Previous studies showed that MCAM is the cell 
surface receptor of galectin-3. The PNA receptor would be extracted by PNA 
purification assay and analysed further. In this study, lactose was used as a 
competitive inhibitor for PNA binding. 
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6.3 Methods 
6.3.1 Assessment of PNA binding to HUVECs by histochemistry 
A T25 flask of 75% confluent HUVECs was released with 1ml trypsin and 
washed with PBS. After incubation for 5 minutes, the cells were suspended at 
1x105 cells/ml with EGM medium before seeding 250μl per well to the 24-well 
plate inserted with glass coverslips. The cells were cultured overnight at 37 °C 
before treatment with 4μg/ml FITC-PNA for 1 or 24 hr. The cells were fixed with 
2% paraformaldehyde and imaged under fluorescence microscope. For each glass 
coverslip, 10 images were randomly taken  
 
6.3.2 Assessment of PNA-FITC binding to HUVEC cell surface in the 
presence of galectin-3 
Endothelial cells (HUVEC) were cultured in five T-25 tissue culture flasks 
(A to E) until 80% confluence. The cells were washed with PBS, and one flask (flask 
A) was introduced with 4µg/ml PNA and the other four (flasks B-E) with 4 µg/ml 
BSA (control) for 24 hr at 37℃. All flasks were washed once with lactose (10μM) 
(to remove any endogenous cell surface galectin-3 binding in B-E), and twice with 
PBS before the cells were released with trypsin, washed once with PBS before 
fixation with 2% paraformaldehyde for 20min. The cells were then washed once 
with PBS before suspension in 1% BSA/PBS for 30 min at room temperature 
before putting into five individual tubes. The cells in Flask A were also washed 
with lactose (to remove PNA binding), released by trypsin and put into a tube. The 
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tubes were the added with PBS, TITC-conjugated anti-mouse antibody (1:500), or 
4µg/ml FITC-PNA without or with 20µg/ml ASF or 4 µg/ml galectin-3 for 1 hr at 
room temperature. The cells were washed once with PBS before analysis by flow 
cytometry to assess the PNA-FITC cell surface binding. The flow cytometry assay 
was operated as described in section 3.12. 
 
6.3.3 Assessment of the effect of PNA-induced cytokine secretion on 
cell adhesion in the presence of galectin-3  
ACA19- and HCT 116 cancer cells were detached using NECDs NECDS (to 
keep cell surface adhesion proteins intact.) After washing with PBS and 
resuspension at 5x106 cells/ml in DMEM, cells were labelled with 10µg/ml calcein 
AM for 30 min at 37°C. Then cells were re-suspended at 1x105 cells/ml with 
serum-free DMEM before application to a new plate of HUVEC monolayer with 
prepared conditioned medium. The prepared conditioned medium was divided 
into five groups with different treatments of: 4µg/ml BSA; 4µg/ml PNA; 4µg/ml 
PNA + 20µg/ml ASF; 4µg/ml PNA + 4µg/ml Galectin-3 and 4µg/ml BSA + 4µg/ml 
Galectin-3. The cells were then maintained at 37°C for 1 hr. After twice washing 
with PBS to remove unbound cancer cells, the monolayer was lysed with 0.25% 
SDS. The endothelial cell-associated fluorescence was read by the fluorescence 
microplate reader at 485nm excitation and 535nm emission. 
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6.3.4 Assessment of PNA-mediated cytokine secretion in the presence 
of galectin-3  
HUVECs with 1.5x105 cells/ml were cultured in 96-well plates overnight 
for monolayer formation. 4μg/ml BSA, 4μg/ml PNA, 4μg/ml recombinant galectin-
3 (Gal3F) or C-terminally truncated galectin-3 (Gal3C) and a combination of 
4μg/ml PNA and 4μg/ml Gal3F or Gal3C were introduced to the culture medium 
for 24 hr at 37°C. Culture medium was collected and levels of cytokines IL-6, MCP-
1, G-CSF, GM-CSF and ICAM-1 were determined by cytokine ELISA.  
 
6.3.5 Extraction of PNA-binding proteins by PNA affinity purification 
PNA-agarose (3ml) was washed three times with 20ml PBS and centrifuged 
at 800  rpm  for 5 min before use. HUVECs were cultured in T25 flasks overnight 
till 100% confluent. Confluent HUVECs were washed three times with PBS before 
being scraped by a cell scraper and then stored at -80 °C till use. After collection 
of ten T25 flask of HUVECs, the HUVECs were defrosted on ice and the supernatant 
was then removed by centrifugation at 2000  rpm  before application of 10ml of 
cell protein extraction buffer. Then the cells were sonicated for 20 seconds for 3 
times on salt ice. The lysate was then centrifuged at 15,000  rpm  for 10 min at 4 °C, 
and supernatant was collected and applied onto the PNA-agarose beads. The 
supernatant-beads mixture was left on a roller overnight at 4 °C to allow PNA 
binding to its ligands. PNA-agarose beads were washed with 20ml PBS to remove 
nonspecific binding. The PNA binding proteins were eluted with 5 ml elution 
solution. The collected elute was then dialyzed against H2O in snake skin fibre 
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overnight to remove galactose, and freeze-dried before analysis by 
electrophoresis. The eluate is also analysed by mass spectrometry.  
 
6.3.6 Assessment of PNA and MCAM co-localization on HUVEC cell 
surface. 
Sub-confluent HUVECs were seeded into 12-well plates inserted with glass 
coverslips. After 24 hr incubation at 37 °C, the cells were washed twice with PBS 
and fixed with 4% paraformaldehyde without detergent. Then cells were 
incubated with 1% BSA for 1hr before application of 4μg/ml FITC-PNA with anti-
MCAM (1:1000) in 2% BSA/PBS (w/v) for 1 hr at room temperature. After three 
washes with PBS, the cells were incubated with Texas Red-Avidin (1:2000) for 1 
hr at room temperature. The cells were washed five times in PBS before being 
mounted with DAPI-containing fluorescent mounting media (Vector Laboratories, 
Burlingame, CA). The slides were analysed using a 3i confocal microscope 
(Marianas SDC, 3i Imaging) and Slidebook 6 Reader version 6.0.4 (intelligent-
imaging). 
 
6.3.7 SiRNA protein knockdown 
80% HUVECs were cultured in 12-well plated for 24 hr. MCAM , PECAM 
siRNA (150pmol) ( Human MCAM/4162, Human PECAM/5175) and control non-
target siRNA (non-targeting siRNA #1) were designed by and purchased from the 
Thermo Fisher company. HUVECs were introduced with 20nM siRNA to MCAM, 
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PECAM and non-target siRNA in 100μl serum free medium for 5min. 2.5μl of 
DharmaFect Transfection Reagent-4 (Thermo Fisher) were dissolved in 100μl 
serum free medium before introducing to HUVECs with 800μl EGM medium for 20 
min at room temperature. HUVECs were incubated for 16 hr at 37 °C before 
replacing the transfection medium with fresh EGM medium. Cells were then 
incubated for 24 hr at 37 °C and were used in two experiments. For 
immunoblotting, cells were lysed by SDS-sample buffer before expression of 
MCAM and PECAM were analysed. For ELISA, cells were introduced with PNA for 
24 hr at 37 °C before concentration of IL-6 and MCP-1 were tested in the culture 
media.  
  
131 
 
6.4 Results 
6.4.1 PNA shows binding to the surface of HUVECs 
75% confluent HUVECs were treated with 4µg/ml FITC-PNA for 1hour and 
24 hours. PNA binding to the endothelial cells can be seen after 1hr and increased 
binding can be seen after 24 hours.(Fig. 6.4.1)  
 
Figure 6.4.1: PNA binding to HUVECs after 24 hours  
HUVECs cells were seeded into 24-well plates with glass coverslips, treated with 
4µg/ml FITC-PNA for 1 hour and 24 hours before fixed and images taken under 
fluorescence microscope. The experiments were repeated three times. Representative 
images are shown in Fig 6.4.1. PNA (green) showed strong binding to HUVEC and the 
binding was still present after 24 hr. Cell nuclei were stained by DAPI (blue).  
1 hour 24 hour 
FITC-PNA Nuclei (DAPI) 
132 
 
6.4.2 PNA-FITC binding to endothelial cell surfaces is partly inhibited 
by galectin-3 
In order to gain an insight of relationship between PNA and galectin-3 
binding to endothelial cell surface, the PNA binding to HUVECs was analysed with 
or without introduction of galectin-3 and the PNA binding ligand ASF that 
expresses TF-antigen.  80% confluent HUVECS were used here and 4µg/ml PNA 
(for the PNA pre-treated group, to test if PNA treatment affects expression of its 
cell surface binding receptors) or BSA were introduced to HUVECs for 24 hr. After 
washing with lactose to remove any endogenous galectin-3 binding (or 
unconjugated PNA binding), the cells were released and fixed. The fixed cells were 
then treated with 4µg/ml FITC-PNA in the presence of 20µg/ml ASF or 4µg/ml 
galectin-3. The flow cytometry analysis showed that PNA binding to HUVECs was 
57.7%. The presence of ASF or galectin-3 caused 59% and 25% reduction 
respectively of PNA binding to the cells. (Fig 6.4.2). Pre-treatment of the cells with 
PNA also results in an increase of PNA cell surface binding (56.2%) (Fig 6.4.2)  
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Figure 6.4.2: PNA binding to the surface of HUVECs is partly inhibited by the 
presence of asialofetuin and galectin-3. 
The HUVECs were treated with 4µg/ml PNA (PNA pretreated group) or 4µg/ml 
BSA for 24 hours. Then the BSA treated cells were collected and fix followed by different 
treatment: 4µg/ml FITC-PNA, 4 µg/ml FITC-PNA+ 20µg/ml ASF, 4µg/ml FITC-PNA+ 
4µg/ml Galectin-3. The PNA binding to the HUVECs was 59% inhibited by ASF and 25% 
by galectin-3. The IgG negative control is shown in blue. 
  
Whole cells 
FITC-anti-mouse antibody 
FITC-PNA 
FITC-PNA + ASF 
FITC-PNA + Galectin-3 
FITC-PNA (PNA pretreated) 
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6.4.3 Investigating the effect of PNA-mediated cytokine secretion on 
cancer cell-endothelial cell adhesion in the presence of galectin-3 
In order to avoid higher number of endothelial cells in PNA-treated group, 
conditioned medium was used in this cell adhesion assay. The conditioned 
medium obtained from PNA-treated HUVECs increased adhesion of ACA19- and 
HCT 116 cells to endothelial cell monolayers by 85±5% and 56±18% in 
comparison to the BSA-treated control group. This PNA-mediated increase of 
cancer cell adhesion was mostly inhibited by ASF, and partially inhibited with the 
present of galectin-3. In addition, the galectin-3 treated group also caused an 
increase in both ACA19- (56±15%) and HCT116 (30±18%) cell adhesion to 
HUVECs when compared to the control group. (Fig 6.4.3)  
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Figure 6.4.3: The effect of PNA-induced cytokine secretion on heterotypic 
cancer cell adhesion with HUVECs can be inhibited by the presence of galectin-3 
HUVECs monolayers were prepared with conditioned medium. Cancer cells ACA19- 
and HCT116 adhesion to fresh HUVECs with or without galectin-3 (4µg/ml). The data are 
expressed as percentage compared with BSA-treated controls from at least 3 independent 
experiments, each in triplicate. Data are expressed as mean value ± SD of triplicate. *P<0.05, 
***p<0.001. (One-way ANOVA followed by Bonferroni) 
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6.4.4 The effect of galectin-3 on PNA-induced cytokine secretion from 
HUVECs. 
Confluent HUVECs cell monolayer were treated with 4µg/ml BSA, 4µg/ml 
PNA, 4µg/ml PNA+ 20µg/ml ASF, 4µg/ml recombinant galectin-3 (Gal-3F) or C-
terminally truncated galectin-3 (Gal-3C) and a combination of 4μg/ml PNA and 
4μg/ml Gal-3(F) or Gal-3(C). The level of IL-6 in the PNA treated cells were 226% 
±22% higher than BSA-treated group in HUVECs. This increase was fully inhibited 
by ASF and mostly inhibited by Gal-3(C). 
The level of G-CSF in the Gal-3(F) treated cell were 407% ± 13% higher 
than BSA-treated group in HUVECs. The galectin-3-induced G-CSF increase was 
partially inhibited by PNA. Similar changes happened with GM-CSF, the Gal-3(F) 
treated cells were 182% ± 3% higher than BSA-treated group. Galectin-3 induced 
G-CSF increase was also inhibited by PNA. Moreover, ICAM-1 secretion was 
increased 238% ± 3% by Gal-3(F) comparing to BSA-treated group, and this 
increase was again partially inhibited by PNA.  
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Figure 6.4.5: Partial competition between the effects of PNA and galectin-3 on 
cytokine secretion by endothelial cells  
HUVECs were treated with 4μg/ml PNA or BSA in the presence or absence 
of 20μg/ml ASF, 4μg/ml recombinant galectin-3(Gal-3F) or C-terminally 
truncated galectin-3 (Gal-3C) for 24 hr before the concentration of cytokines in 
the culture medium were analyzed by ELISA. Data are presented as mean ± SD in 
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comparison to control, from 3 independent experiments. ***p<0.001. (One-way 
ANOVA followed by Bonferroni) 
6.4.5 Identification of PNA binding ligands on endothelial cell surface 
by PNA affinity purification and mass spectrometry 
HUVECs were collected by cell scraper and treated with cell protein 
extraction buffer before sonication. After ultra-centrifugation, the supernatants 
were applied to the PNA-agarose beads. Bound proteins were then eluted from the 
beads with galactose (2M). The eluted proteins were dialyzed against H2O to 
remove galactose. The proteins were then freeze-dried and analysis by 
electrophoresis and silver staining, and mass spectrometry. The silver staining 
showed several strong bands between 20 and 250kDa. PNA affinity purification 
followed by Mass spectrometry analysis identified a number of proteins that were 
extracted by PNA affinity purification. The highest scored cell membrane 
glycoproteins in the hit list were MCAM and PECAM. The silver staining also 
showed proteins in that range. (Fig 6.4.6)  
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Figure 6.4.6: Identification of endothelial cell surface PNA-binding proteins  
PNA affinity purification followed by mass spectrometry identify MCAM 
and PECAM as PNA binding cell surface proteins from HUVECs. PNA blotting with 
silver staining shows similar binding of PNA to a number of proteins in HUVECs. 
Mass spectrometry results showed MCAM and PECAM were possible PNA binding 
proteins. MW, molecular weight.  
140 
 
6.4.6 MCAM is the one of the major PNA-binding proteins on the 
endothelial cell surface 
80% confluent HUVECs were treated with FITC-PNA and anti-MCAM 
antibody for 1hr. The cell surface adhesion molecule MCAM was labelled by using 
the Texas Red-Avidin before endothelial cells being mounted by DAPI-containing 
fluorescent mounting medium. Substantial colocalization of PNA binding to 
endothelial cells with MCAM is shown (due to time constrains, co-localization of 
PNA with PECAM was not studied in this study).  
(Fig 6.4.7)  
Figure 6.4.7: Co-localization of PNA with MCAM in HUVECs 
After treatment of HUVECs with 4µg/ml PNA for 60 min, the cells were 
labelled, and MCAM (red) and PNA (green) immunohistochemistry was conducted 
by confocal microscopy. Cell nuclei were stained by DAPI (blue). 
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6.4.7 Investigation of the effect of PNA binding proteins MCAM and 
PECAM on the endothelial secretion of PNA-mediated cytokine 
To determine whether interaction between PNA and cell membrane 
proteins MCAM or PECAM are responsible for PNA-mediated cytokine secretion, 
we treated the HUVECs with 4μg/ml BSA, 4μg/ml PNA, 20μg/ml ASF, and 2μg/ml 
of anti-MCAM or anti-PECAM antibody for 24 hr. Then the cultured medium was 
collected and analysed by ELISA. PNA binds to TF antigen carried on ASF, the PNA 
effects should therefore be inhibited by ASF. The level of IL-6 released by the PNA 
treated cells was 236±18% higher than the BSA-treated group and the increase 
was fully inhibited by ASF (99±12%). PNA-mediated increase of IL-6 secretion 
was shown to be partially inhibited by the presence of anti-MCAM (57±14%) and 
anti-PECAM antibody (48±17%). PNA treatment resulted in increase of MCP-1 
secretion by 405±15% comparing to the BSA-treated group and the increase was 
inhibited by ASF (82±1%) and partially by anti-MCAM antibody (60±19%) and 
anti-PECAM antibody (57±44%). (Fig 6.4.8) It is known that MCAM is also the 
receptor for galectin-3.  
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Figure 6.4.8: PNA binding to cell surface MCAM and PECAM are responsible for 
PNA-mediated cytokine secretion 
HUVECs were treated with 4ug/ml PNA or BSA in the presence or absence of 20μg/ml 
ASF, antibodies against MCAM (2μg/ml) or PECAM (2μg/ml) for 24hr followed by ELISA 
analysis of the concentration of cytokines in the culture medium. Data are presented as Mean 
± SD in comparison to control, from 3 independent experiments. ***p<0.001. (One-way ANOVA 
followed by Bonferroni) 
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6.4.8 Suppression of MCAM and PECAM expression on endothelial 
cells 
To determine whether MCAM and PECAM are the major receptors for PNA, 
the expression of MCAM and PECAM from HUVECs was suppressed by siGENOME 
siRNA. SiRNA treatment showed a 53% blockage of cellular MCAM expression, and 
79% blockage of cellular PECAM expression when comparing to cells treated with 
control siRNA (Fig 6.9.9).  
 
Figure 6.4.9: Suppression of MCAM and PECAM expression in endothelial cell 
HUVECs were treated with 150pmol of control siRNA, MCAM siRNA or PECAM siRNA 
for 36 hr. The cells were lysed and analyzed for MCAM and PECAM expression by 
immunoblotting. The cell lysates were separated by SDS-PAGE and transferred to 
nitrocellulose membrane. The membranes were incubated with primary antibodies against 
MCAM (1:500), PECAM (1:500) or actin (1:1000) as control for 24 hr. After secondary 
antibody, the blots were washed and developed Super Signal kit. The protein bands on the 
blots were visualized with the Molecular Imager Gel DocTM XR system (Bio-Rad). 
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6.4.9 Investigation of the influence of suppression of MCAM or PECAM 
expression on PNA-induced endothelial cytokine secretion 
To investigate whether MCAM and PECAM are the functional ligands 
responsible for PNA-induced cytokine secretion by the endothelium, siRNA 
treatment was applied to the endothelial cells and suppression of  MCAM and 
PECAM expression was confirmed by immunoblotting. The suppressed cells were 
then introduced with 4µg/ml PNA and IL-6 and MCP-1 concentrations in the 
culture media then determined by ELISA. Treatment with 4μg/ml PNA increased 
IL-6 concentration to 5.61ng/ml (± 0.7ng/ml), a 3.96-fold increase in the control-
siRNA treated HUVECs cells compared with BSA. The MCAM siRNA+PNA group 
showed marked inhibition of IL-6 secretion (67±5%) in comparison to the control 
cells treated with PNA. The PECAM siRNA+PNA group also showed full blockage 
of IL-6 endothelial secretion (71±5%). Within the control siRNA cells, PNA 
induced MCP-1 secretion to 16.93±2.41ng/ml which is 3.3-fold higher than the 
control group. MCAM and PECAM siRNA suppressed cells treated with PNA 
showed major reduction of MCP-1 secretion (83±5%; 81±8%). In conclusion, 
suppression of either MCAM or PECAM resulted in loss of the PNA effect on IL-6 
and MCP-1 secretion. (Figure 6.4.10) 
145 
 
 
Figure 6.4.10: Suppression of MCAM and PECAM expression in endothelial cells 
blocks PNA-induced cytokine secretion 
HUVECs were treated with 150pmol of control siRNA, MCAM siRNA or PECAM siRNA 
for 36 hr. The cells were treated with 4μg/ml BSA or 4μg/ml PNA and the concentration of IL-
6 and MCP-1 in the culture medium was analyzed by ELISA. Data are presented as mean ± SD 
in comparison to control, from 3 independent experiments. ***p<0.001. (One-way ANOVA 
followed by Bonferroni) 
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6.5 Discussion 
In this part of the study, the PNA histochemistry analysis showed strong 
PNA binding to the endothelial cell surface. Flow cytometry analysis showed that 
PNA binding to the surface of endothelial cells was partly inhibited by ASF (59%) 
and galectin-3 (25%). PNA-agarose affinity purification followed by mass 
spectrometry analysis identified MCAM and PECAM as two PNA binding cell 
surface glycoproteins. PNA-induced cytokine secretion was shown to be partly 
inhibited by the presence of anti-MCAM or anti-PECAM antibody. PNA-mediated 
cytokine secretion was largely lost when MCAM or PECAM expression was 
suppressed by siRNA treatment. To test whether PNA and MCAM were co-
localized on the cell surface, confocal microscopy was performed without addition 
of detergents such as Triton-100. ASF was used as a competitive inhibitor of 
binding by PNA. Galectin-3 which also binds to TF antigen was also used here as a 
potential competitive PNA-binding inhibitor.  The presence of galectin-3 caused 
25% reduction of PNA binding to the cell surface, indicating that PNA and galectin-
3 share some but not all cell surface binding receptors. PNA pre-treatment was 
shown to increase subsequent PNA binding on the endothelial cell surface when 
compared with the non-pretreated group. This indicates that PNA-induced 
cytokine secretion likely increases the expression of PNA endothelial cell surface 
receptors.  
Melanoma cell adhesion molecule (MCAM) also known as CD146 or cell 
surface glycoprotein MUC18, is a cell surface adhesion molecule with a molecular 
weight of 113kDA and is identified as a marker for cancer diagnosis, prognosis, 
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and response to treatment. [313] MCAM is a membrane glycoprotein consisting of 
an extracellular domain containing 8 putative N-glycosylation sites, a single 
transmembrane domain and a cytoplasmic tail. [314, 315] The glycosylation of 
MCAM comprises 35% of the total molecular weight. MCAM was viewed as an 
endothelial cell marker previously [316] but is expressed by melanoma cells and 
plays an important role in melanoma metastasis. [317, 318] The MCAM protein is 
composed of two isoforms, CD146 long and CD146 short isoforms. These two 
isoforms can be identified by their different lengths of intracellular domain. [319] 
The CD146 long form consists of a 63-aa intracellular fragment including 5 protein 
kinase binding sites and 2 putative endocytic domains, while the CD146-short 
form consists of a truncated cytoplasmic tail that lacks endocytosis motifs and a 
protein kinase site. [320] Both the short and long forms are expressed by 
endothelial cells while melanoma cells express mainly the long isoform. On the 
vascular endothelial cell surface, MCAM is identified as an immunoglobulin 
superfamily member of endothelial cell surface adhesion molecules with a key 
effect on cell adhesion. [321] MCAM is also involved in cell-matrix interactions and 
various kinds of cell-cell interaction in vascular endothelial cell activities such as 
angiogenesis, migration and engagement in outside-in signals. Although the 
natural MCAM ligand continues to be elusive, its engagement plays an important 
role in activation of several signalling pathways including p38, PKC and PI3K/AKT. 
Recent studies have shown that the interaction between MCAM and VEGFR-2 is 
the key to activation of p38 and AKT signalling on the endothelial cell surface, and 
therefore promotes cell migration. [322] In addition, MCAM interaction with 
Laminin-411 allows Th17 cell entry to the central nervous system and promotes 
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inflammation. [323] There is also evidence that MCAM binding to Netri-1 activates 
downstream signalling, thus again enhancing cell proliferation, adhesion, 
migration and angiogenesis. [320] Recent studies have shown interaction 
between MCAM and exogenous galectin-1 with inhibition of galectin-1-induced 
endothelial cell apoptosis. [324]  
Platelet endothelial cell adhesion molecule (PECAM) is also known as CD31 
with a molecular weight of approximately 130kDa. [325] PECAM is a 
transmembrane glycoprotein and is a member of the immunoglobulin superfamily 
of cell adhesion molecules. [326] Due to its differing glycosylation, the molecular 
weight of PECAM varies between different cell types. [327] PECAM was first 
characterized as a cell-surface protein before being identified as an endothelial 
cell junction molecule. Recent studies have found that PECAM is expressed on the 
cell surface of many cell types including platelets, monocytes, and neutrophils.  
[328]  PECAM is commonly expressed at the intercellular junctions on endothelial 
cells and on T cells. Previous studies have shown that PECAM plays an important 
role in leukocyte migration through vascular endothelial cells. [329, 330]PECAM 
is composed of a large extracellular fragment of 574 amino acids containing nine 
N-glycosylation sites, a single trans-membrane region of 18 hydrophobic 
compounds and a cytoplasmic tail of 118 amino acids. [327] Its glycosylation 
accounts for 40% of the molecular weight. The cDNA of PECAM has an 
approximately around 70% homology between murine and human sequence. 
[331]  A structure containing six Ig-like homology domains is presented on its 
extracellular region and this is believed to play a critical role in cell adhesion. The 
structure of this domain 2 carries an identification sequence for 
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glycosaminoglycan binding which is found to play a key role in PECAM-1 
heterotypic adhesion. In endothelial cell culture, earlier data showed an inhibited 
cell-cell interaction in the presence of anti-PECAM antibody. [332] In 
inflammation, the leukocyte-endothelial interaction activates a cascade of cell 
activities involving cytokines, chemoattractant and cell adhesion molecules. In 
vivo and in vitro studies have suggested that PECAM has an inhibitory effect at 
inflammatory sites for neutrophils. [333] Like MCAM, PECAM has also been 
identified as a biomarker for different stages of cancer metastasis. Both MCAM and 
PECAM are associated with metastasis and progression of melanoma, breast and 
prostate cancer. As a member of the Ig superfamily, PECAM is involved in 
angiogenesis, and has a potential role in cell migration, polarity and extravasation. 
For example, the expression of PECAM is stimulated by the VEGF secreting from 
tumour cells, and PECAM acts as a regulator in cell migration by its function on 
modulating cell-matrix and cell-cell interactions. [334, 335] Previous study also 
showed that PECAM expressed from melanoma cells participated in cancer cell- 
vascular endothelial cell adhesion, and promotes metastasis.  
As mentioned above, the cell surface adhesion molecules MCAM and 
PECAM are both reported to interact with VEGFR in endothelial cells, and their 
interaction affects AKT signalling which could regulate various cytokine secretion 
such as IL-6. [336] This study shown that the PNA-induced cytokine secretion of 
IL-6 and MCP-1 were partially inhibited with the present of antibodies against 
MCAM and PECAM. In addition, the endothelial secretion of IL-6 and MCP-1 were 
markedly reduced in MCAM/PECAM siRNA suppressed endothelial cells. It seems 
that the interaction between PNA and its cell surface receptors MCAM and PECAM 
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involves several cell signalling mechanisms such as PI3K-AKT signalling in human 
endothelial cells. It remains to be investigated how MCAM and PECAM mediate 
PNA-induced endothelial cytokine secretion, and activation of various signal 
transduction pathways may positively regulate these MCAM/PECAM-PNA 
interactions.  
The discovery in this study that galectin-3 can substantially inhibit PNA–
induced cytokine secretion suggests that PNA and galectin-3 might share binding 
to some of the same endothelial cell surface glycoproteins. Both MCAM and 
PECAM were found in the extracts from galectin-3 affinity purification but only 
MCAM was shown to interact directly with galectin-3. [218] Inhibition of either 
MCAM or PECAM on their own only partially inhibits PNA-mediated IL-6 and MCP-
1 secretion indicating that, in contrast to the action of galectin-3, both MCAM and 
PECAM may be involved in PNA-mediated cytokine secretion. In addition, this 
suggested that we should also look into the interaction between PNA and 
MCAM/PECAM, this protein-protein interaction can be analysed by co-
immunoprecipitation.  
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CHAPTER 7 Investigating the mechanism of PNA interaction with 
MCAM and PECAM in endothelial cell signaling 
7.1 Hypothesis and Aim 
7.1.1 Hypothesis 
Induction of endothelial cytokine secretion by PNA following interaction 
with MCAM and PECAM will involve one or more cell signaling pathways. 
  
7.1.2 Aim 
To study the cell signalling pathways involved in the interaction of PNA 
with MCAM and PECAM in endothelial cells 
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7.2 Introduction 
Studies reported previously in this thesis have shown that PNA induces 
endothelial secretion of metastasis-associated cytokines IL-6 and MCP-1 and this 
effect is related to PNA binding to cell surface MCAM and PECAM. It is shown that 
the PNA-induced cytokine secretion can be inhibited with the present of 
antibodies against MCAM and PECAM. [337] IL-6 also acts predominantly in the 
activation of Janus Kinase (JAK) signaling which contributes to initiation of the 
Signal Transducer and Activator of Transcription protein (STATS) family. [338, 
339] In addition, IL-6 is also affected by the mitogen-activated protein kinase 
(MAPK) signaling cascade which mediates IL-6 mRNA stability. [340] 
Furthermore, the chemotactic cytokine MCP-1 is also shown to mediate various 
cell signal transduction pathways by inducing kinase activity and having 
multifunctional effects on endothelial cell chemotactic activity. [341]  
The PNA receptors MCAM and PECAM are also reported to participate in 
some important cell signalling pathways. [342] MCAM acts as a downstream 
target of the CD44 signalling pathway which leads to inhibition of breast cancer 
cell invasion. [343] In melanoma cells, MCAM expression increases 
phosphorylation of AKT. The expression of MCAM is also strongly linked to the 
activation of AKT. In contrast, phosphorylation of MAPK was reduced after 
activation of MCAM in melanoma cells. [344] In hepatocellular carcinoma, PECAM 
expression mediated by integrin β1, acts as a promoter of cell invasion and 
metastasis. The expression of PECAM is responsible for the downstream 
activation of FAK/AKT signalling pathway. [345] Recent studies also showed that 
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PECAM expression has a regulatory effect on phosphorylated STAT signal 
transduction. [346]  
This part of the study aims to investigate the signalling pathways induced 
by PNA interaction with MCAM and PECAM in the PNA-mediated secretion of IL-6 
and MCP-1. 
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7.3 Methods 
7.3.1 Assessment of PNA related signaling pathway by protein 
phosphor-kinase array 
Sub-confluent HUVECs were treated with 4µg/ml PNA or BSA for 24 hr. 
Cells were washed, lysed and analysed using the Proteome Profiler human 
phosphor-kinase array kit according to the instructions of the manufacturer. The 
phosphor-array kit provided membranes with antibodies against 43 common 
kinase phosphorylation sites.  Following the instruction, the membranes were 
prepared, washed and incubated with cell lysed samples before being visualized 
by the Molecular Imager® Gel DocTM XR system and analysed using Image Lab 
software version 5.2.1 (Bio-Rad). 
 
7.3.2 Assessment of the effect of PNA treatment on cell protein 
tyrosine phosphorylation 
Sub-confluent HUVECs were cultured in 12-well plates overnight to form a 
monolayer. Then HUVECs were treated with different concentrations of PNA (0, 1, 
2, 4, 8 µg/ml) for 1 hour at 37°C. Cells were washed in ice cold PBS and lysed in 
SDS-sample buffer with beta-mercaptoethanol. The samples were then analysed 
by SDS-PAGE and western blotting with antibodies (1:1000) against AKT, 
phosphor-AKT, PRAS40 and phosphor-PRAS40. After three washes with 0.05% 
Tween 20/PBS, the blots were incubated with peroxidase-conjugated anti-rabbit 
antibodies (1:2000) as secondary detecting antibody. After development and 
155 
 
imaging, the immunoblotting membranes were then stripped using stripping 
buffer for 30 minutes in a warm water bath, and then re-probed with actin 
antibody (1:1000) and anti-mouse antibody (1:4000) for validation of protein 
loading. The blots were visualized with the Molecular Imager® Gel DocTM XR 
system and analysed using Image Lab software version 5.2.1 (Bio-Rad). 
  
7.3.2 Assessment of the effect of protein kinase inhibitors on PNA-
mediated cytokine secretion from endothelial cells 
HUVECs with 1.5x105 cells/ml were cultured in 96-well plates overnight 
for monolayer formation. The cells were divided into two groups and treated with 
4µg/ml PNA or 4µg/ml BSA. Each group was then treated with 5µM PI3K inhibitor 
Wortmanin, 20µM LY294002, 20µM MEK1/2 inhibitor PD98059, and 50 µM 
STAT3 inhibitor DPP individually for 24 hr at 37 °C. The cell culture medium was 
collected and levels of cytokines IL-6 and MCP-1 were determined by cytokine 
ELISA. 
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7.3.3 Assessment of the effect of protein kinase inhibitors on the PNA-
mediated endothelial cell growth  
HUVECs 5x105 cells/ml were cultured in 96-well plates at 37°C for 1hr. The 
cells were then treated with 4µg/ml BSA, 4µg/ml PNA, 4µg/ml BSA with four 
individual kinase inhibitors (5µM Wortmanin, 20µM LY294003, 20µM PD98059 
and 50µM DPP) and 4µg/ml PNA with the same four individual kinase inhibitors. 
Endothelial cells were then cultured for 24 hr at 37°C before labelling with 2µl of 
Calcein AM for 30 min at 37°C. After three PBS washes, the endothelial cell-
associated fluorescence was read using a fluorescence microplate reader at 
485nm excitation and 535nm emission (infinite 200, TECAN).  
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7.4 Results 
7.4.1 PNA increases phosphorylation of AKT, STAT3, PRAS40 and RSK 
in endothelial cells 
Treatment of HUVECs with PNA was shown to enhance the 
phosphorylation of several key cell signalling proteins STAT3, PRAS40, AKT1/2/3 
and RSK1/2/3. STAT3 phosphorylation at Y705 and S727 was increased by 2.86- 
and 3.32-fold respectively.  AKT1/2/3 phosphorylation at T308 site was increased 
by 2.81-fold. RSK1/2/3 phosphorylation at S380, S586, S377 was increased by 
1.91-fold, and the PRAS40 phosphorylation at T246 site was elevated 1.86-fold. 
(Fig 7.4.1) 
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Figure 7.4.1: The presence of PNA increases tyrosine phosphorylation of several 
key signalling proteins in HUVECs 
HUVECs were treated with 4 µg/ml PNA or 4 µg/ml BSA (control) for 30 minutes 
before analysed by the Human Phosphor-Kinase Array. PNA presence increased the 
phosphorylation of AKT, TAT3, RSK and PRAS40 when compared to the BSA-treated control 
group. 
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7.4.2 Assessments of PNA effects on AKT and PRAS40 phosphorylation 
The phosphor-kinase array analysis showed PNA effects on 
phosphorylation of four kinases at respective phosphorylation sites. In order to 
further study the mechanism of PNA-induced kinase phosphorylation, the effect 
of different concentrations of PNA on these kinases was studied by 
immunoblotting. HUVECs were treated with different concentrations of PNA (0, 1, 
2, 4, 8µg/ml) and the cells were collected and analysed by immunoblotting with 
antibodies (1:1000) against AKT, phosphor-AKT, PRAS40, phosphor-PRAS40, 
STAT3 and phosphor-STAT3.  
The immunoblotting results show that PNA increased the level of 
phosphorylated AKT compared to the expression of AKT. The PNA treatment also 
induces a similar dose-dependent increase in PRAS40 phosphorylation. STAT3 
phosphorylation showed no significant changes after PNA treatment. (Fig 7.4.2)  
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Figure 7.4.2: PNA activates AKT, PRAS40 and STAT3 signaling 
HUVECs were treated with 0, 1, 2, 4 and 8µg/ml PNA and lysed with 2% sample buffer. 
The samples were then analysed by immunoblotting with antibody (1:1000) against AKT, 
phosphor-AKT, PRAS40, phosphor-PRAS40, STAT3 and phosphor-STAT3. PNA is shown to 
increase the levels of phosphorylated AKT (60 kDa), PRAS40 (40 kDa) and STAT3 (80 kDa). 
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7.4.3 PNA-induced cytokine secretion is inhibited by the presence of 
protein kinase inhibitors against PI3K, MEK1/2 and STAT3 
To confirm the involvement of these kinases in PNA-induced cytokine 
secretion from HUVECs, the HUVECs were treated with PNA in the presence or 
absence of 4 different kinase inhibitors, PI3K inhibitor Wortmanin (5µM), 
LY294002 (20 µM), MEK1/2 inhibitor PD98059 (20µM), and STAT3 inhibitor DPP 
(50µM). The level of IL-6 in the PNA treated cells was 440±27% higher comparing 
to the BSA-treated control group. This increase was significantly inhibited by the 
present of each of these kinase inhibitors Wortmanin (70%), LY294002 (97%), 
PD98059 (67%) and DPP (54%). PNA-treatment increased MCP-1 level by 
838±390% and this increase was inhibited by the present of Wortmanin (86%), 
LY294002 (96%), PD98059 (87%) and also DPP (74%). (Fig 7.4.3) 
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Figure 7.4.3: PNA induced secretion of IL-6 and MCP-1 from HUVECs was 
inhibited by inhibitors of P13K, MEK1/2 and STAT3 kinases.  
The HUVECs were treated with 4 µg/ml PNA or BSA for 24 hr in the presence and 
absence of four kinase inhibitors, PI3K inhibitor 5µM Wortmanin (MW), 20µM LY294002 (LY), 
20µM MEK1/2 inhibitor PD98059 (PD), and 50µM STAT3 inhibitor DPP (DPP) before the 
concentrations of IL-6 and MCP-1 in the culture medium were analysed by ELISA. Data are 
presented as Mean ± SD in comparison to control, from 3 independent experiments. 
***p<0.001. (One-way ANOVA followed by Bonferroni) 
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7.4.4 PNA-induced endothelial cell growth is inhibited in the presence 
of kinase inhibitors 
The results shown the endothelial cell growth was 160±5% higher in the 
PNA-treated group than the BSA-treated control. This induced endothelial cell 
growth is mostly inhibited with the present of four kinase inhibitors, Wortmain 
(74%), LY294002 (92%), PD98059 (70%) and DPP (63%). (Fig 7.4.4)  
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Figure 7.4.4: PNA-mediated endothelial cell growth is inhibited in the presence 
of kinase inhibitors 
 Endothelial cells were prepared and incubated with 4µg/ml BSA and 4µg/ml PNA 
with or without four kinase inhibitors, 5µM Wortmanin, 20µM LY294002, 20µM PD98059 and 
50µM DPP for 24hr. Endothelial cells were labelled with Calcein AM and the HUVECs cell 
survival was measured using a fluorescence microplate reader. The data are expressed as 
percentage compared with BSA-treated controls from three independent experiments, each 
in sextuplicate. Data are expressed as mean value ± SD of triplicate. ***p<0.001. (One-way 
ANOVA followed by Bonferroni) 
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7.5 Discussion 
This part of the study shows that PNA treatment of HUVECs increases cell 
phosphorylation of AKT, STAT3, PRAS40 and RSK in a PNA-dose-dependent way 
and the increase was inhibited by the presence of four kinase inhibitors PI3K 
inhibitor Wortmanin, LY294002, MEK1/2 inhibitor PD98059, and STAT3 
inhibitor DPP.  
AKT, also known as protein kinase B, is a serine/threonine protein kinase 
that has three isoforms AKT1, AKT2 and AKT3. AKT is well known for its 
regulation of a number of cell functions such as metabolism, proliferation, 
apoptosis and angiogenesis. [347] It is reported that AKT plays a key role in 
multiple cell signalling pathways and in determining cell death and survival. [348] 
The AKT’s effect varies in different ways. For examples, AKT stimulates cell 
growth factors to promote cell survival, and inactivates pro-apoptotic proteins to 
prevent apoptosis. [349] AKT is composed of an N-terminal domain, a C-terminal 
domain and a central domain. A structure of 100 amino acids similar to the 3-
phosphinositide binding molecules on its N-terminal domain helps its interaction 
with membrane lipid ligands involving the phosphatidylinositol-3,4,5-
triphosphate as called as PIP3 which is associated with the PI3K downstream 
signaling pathway. [350-352] 
PI3Ks are a family of enzymes identified with protein and lipid kinase 
activity which is activated by different membrane receptors. Even though the 
PI3Ks have different structure, expression or even substrate specificity, they all 
share a common function which catalysis the phosphorylation of different 
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membrane proteins. PI3Ks can be classified into three families by their protein 
structure and substrate specificity. [353, 354] The most studied family is the four 
Class I PI3K isoforms which is PI3Kα, β, γ, δ. There are three isoforms in Class II 
PI3K (PI3KC2α, C3β, C3γ) and also the single class III PI3K. [355] Class I PI3Ks 
participated in immune regulation and play an important role in related signaling 
pathways. [356] In dendritic cells, PI3K signaling induced by CD80/CD86, 
stimulates pro-inflammatory cytokine secretion through downstream AKT 
phosphorylation and mediates IL-6 expression. [357] It is shown by many studies 
that the PI3K signal pathway is one of the most common signaling pathways 
pathogenically affected in cancer, suggesting that PI3K can be used as a target for 
cancer treatment. Earlier studies in head and neck squamous cell carcinoma 
(HNSCC) showed that MEK- and PI3K-associated signal pathways play a critical 
role in hepatocyte growth factor (HGF) inducing expression of angiogenesis 
factors like IL-8 and vascular endothelial growth factors, leading to increased 
angiogenesis thus promoting cancer development. [358, 359]  
PRAS40 is a substrate of AKT and has a molecular weight of 40kDa. PRAS40 
acts as a mammalian target of the heterotrimeric rapamycin (mTOR) protein 
kinase. [360] After activation of mTORC1 kinase, the phosphorylation of PRAS40 
is increased [361] Phosphorylation of various substrates results from activation 
of mTOR in reaction to growth factors and nutrients, including S6 kinase 
phosphorylation mediated by mTORC1, and AKT phosphorylation by mTORC2. 
[362] Modifications in mTOR action and AKT have been associated with 
progression of various diseases including type 2 diabetes and cancer. [363] 
Investigation of mTOR-binding partners characterize PRAS40 as both substrate 
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and also a component of mTORC1.  PRAS40's phosphorylation is activated by AKT 
and results in PRAS40's dissociation from mTORC1 and an inhibitory control on 
mTORC1 action. [364] Gene silencing studies suggest that PRAS40 is in a similar 
way required for the mTORC1 complex's activity. Consequently, the role of 
PRAS40 in the AKT-mTOR signalling pathway is likely to play an important role in 
disease and health. 
This study showed that PNA induces phosphorylation of all these four 
kinases AKT, STAT3, PRAS40 and RSK. The presence of kinase inhibitors against 
PI3K, MEK1/2, and STAT3 inhibits PNA induced phosphorylation of these kinases 
and prevents the increase of IL-6 and MCP-1 production by PNA. In addition, the 
PNA-mediated endothelial cell growth is reduced in the presence of these kinase 
inhibitors. These data indicate that AKT, STAT3, PRAS40 and RSK signalling are 
involved in the increased secretion of IL-6 and MCP-1 from endothelial cells 
mediated by interaction of PNA with the endothelial cell surface proteins MCAM 
and PECAM. It is not yet clear whether the signalling pathways mentioned above 
are induced indirectly by increased cytokine secretion of IL-6 and MCP-1 from 
PNA-treated endothelial cells, or are induced more directly by interaction 
between PNA and its receptors MCAM and PECAM.  
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CHAPTER 8 Summary of the main findings 
• Galectin-3 at pathological concentrations induces dose-dependent 
secretion of four cytokines (G-CSF, GM-CSF, IL-6 and sICAM-1) from both micro-
vascular and macro-vascular endothelia cells.  
• PNA at pathological concentrations induced cytokine secretion of 
IL-6 and MCP-1 from both microvascular and macrovascular endothelial cells. 
• The PNA-induced secretion of IL-6 and MCP-1 from endothelial cells 
in both dose-dependent and time-dependent manner. 
• The PNA-induced secretion of IL-6 and MCP-1 increases cancer cell 
heterotypic adhesion with endothelial cells 
• The PNA-induced secretion of cytokines increases endothelial cell 
growth.  
• The PNA-induced secretion of cytokines promotes endothelial cell 
tubule formation in angiogenesis. 
• The PNA-induced secretion of cytokines enhances the endothelial 
expression of cell surface adhesion molecules including integrin α5β1, integrin α5β3, 
E-selectin and VCAM-1 on cell surface of HUVECs. 
• PNA shows strong binding on the endothelial cell surface after 24 
hr. 
• The PNA-induced cytokine secretion from endothelial cells is 
partially inhibited by galectin-3. 
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• The PNA-induced cancer cell-endothelial cell adhesion is partially 
inhibited by galectin-3. 
• The PNA induced endothelial secretion of IL-6 and MCP-1 is 
partially inhibited by galectin-3. 
• Galectin-3 also shows binding to cancer cells and induces tyrosine 
phosphorylation. 
• PNA-agarose affinity purification extracts cell surface glycoprotein 
MCAM and PECAM 
• MCAM and PECAM are the major PNA-binding proteins on 
endothelial cell surface. 
• The PNA-induced cytokine secretion is inhibited by a combination 
of anti-MCAM/anti-PECAM antibodies. 
• PNA-induced secretion of IL-6 and MCP-1 is regulated with 
suppression of MCAM and PECAM expression on endothelial cell surface. 
• PNA induces phosphorylation of AKT, STAT3, PRAS40 and RSK in 
endothelial cells. 
• PNA-induced cytokine secretion of IL-6 and MCP-1 is inhibited in 
the presence of kinase inhibitors against PI3k, MEK1/2 and STAT3.  
Figure 8: The schematic diagram of main findings 
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CHAPTER 9 General discussion and implications for future 
studies 
9.1 Discussion 
The results in this thesis show that PNA at levels similar to that found in the 
circulation of people after eating 250g peanuts induces secretion of IL-6 and MCP-
1 from both human microvascular and macrovascular endothelial cells. The 
possible relevance of this to human health is further supported by the known 
marked resistance of peanut lectin to degradation by proteases or cooking. [160] 
The PNA-induced secretion of these cytokines promotes the expression of several 
endothelial cell surface adhesion molecules such as E-selectin and VCAM-1, that 
support adhesion of cancer cells to blood vascular endothelium. PNA-induced 
secretion of these cytokines also increases endothelial cell migration and tubule 
formation in angiogenesis. Two cell surface glycoproteins MCAM and PECAM were 
identified to be the functional PNA ligands responsible for PNA induced secretion 
of these cytokines. PNA binding to MCAM and PECAM was shown to be partially 
inhibited by galectin-3, suggesting they share some but not all binding ligands. 
These discoveries indicate that PNA, like galectin-3, can interact with endothelium 
and enhances endothelial secretion of cytokines which in turn promotes tumour 
cell adhesion, migration and angiogenesis in metastasis. Thus, in addition to its 
direct effect on tumour cell adhesion and aggregation by interaction with cancer 
associated MUC1 shown in our earlier study, PNA presence in the circulation also 
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promotes metastasis indirectly by inducing endothelial secretion of metastasis 
cytokines.  
PNA and galectin-3 are both shown to induce IL-6 secretion. Galectin-3 also 
induces secretion of G-CSF, GM-CSF and ICAM-1 while PNA induces MCP-1 
secretion. The difference in the effects of galectin-3 and PNA on secretion of these 
cytokines is in keeping with the partial competition of galectin-3 with PNA binding 
on endothelial cells and on PNA-induced cytokine secretion. This is also in keeping 
with the difference in effect of galectin-3 and PNA on the expression of endothelial 
cell adhesion molecules. The secretion of cytokines induced by PNA and galectin-
3 both increase the expression of α5β1 integrin, E-selectin, VCAM-1 and ICAM-1.  
While the cytokines induced by PNA also increases α5β3 integrin expression, 
those induced by galectin-3 have no effect on α5β3 integrin expression. The 
integrin α5β1 is known as a fibronectin receptor, was first identified as a cell 
adhesion molecule and acts as receptor for ECM proteins and transmembrane 
proteins. (220) With its regulation function in intracellular signaling and cell 
activities including proliferation, differentiation and migration, α5β1 is also a 
therapeutic target in ovarian cancer and glioma. (221, 222, 223) E-selectin 
activated by cytokines in endothelial cell is reported previously as a mediator of 
cell adhesion and inflammation. (224, 225). In the cancer microenvironment, E-
selectin is a potential biomarker for detection and monitoring of lung, breast and 
colon cancer (226, 227, 228) Circulating E-selectin was reported to induce cancer 
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cell migration and tumour growth through interaction with CD44. Alteration of 
ICAM-1 expression is correlated with metastasis in breast cancer. (230) (229) 
ICAM-1 was shown by a previous study to bind to the cell surface MUC1, which is 
a natural high affinity galectin-3 ligand and carries TF antigen that is the specific 
binding structure of PNA. These cell surface receptors were activated by PNA-
mediated cytokines and contribute to many important cellular and pathological 
functions. The increased expression of these cell surface adhesion molecules by 
PNA-induced cytokines thus could have fundamental impact on cancer metastasis 
Lectins in plants such as legumes have been known for over a century. 
Earlier studies on lectins were more focused on their roles in immune and 
inflammation responses. More recently, interaction between lectins and cancer 
cells started to attract attention. Lectins with their specific binding to 
carbohydrates on cell membrane are involved in cell aggregation and adhesion. 
(214) Animal studies have shown that Viscum album agglutinin-1 (VAA-1) from 
mistletoe extracts, increase IL-12 secretion and stimulate cytotoxic activity of 
natural killer (NK) cells. (213), supporting an anticancer function of VAA-1. (214)  
Previous studies have shown that PNA stimulates proliferation of colon, 
melanoma and breast cancer cells (208, 209, 211, 212). IL-6 and MCP-1 are known 
to affect a range of cancer cell activities such as stimulating cancer-related 
inflammation from cancer cells or endothelial cells and enhance cell growth, 
invasion and metastasis. (215, 216, 217, 218, 219) The increased secretion of IL-6 
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and MCP-1 by PNA would be expected to have an impact of metastasis. Thus, in 
addition to the direct influence of PNA in the circulation on metastasis by 
interaction with cancer-associated MUC1, PNA also has an indirect influence on 
cancer metastasis by interaction with the blood vascular endothelium to induce 
secretion of IL-6 and MCP-1 cytokines. This provides further support to the 
hypothesis that regular consumption of peanuts by cancer patients might increase 
the risk of metastasis and mortality. Although further studies are needed, these 
data indicate that the presence of PNA in the blood stream of cancer patients who 
regularly eat peanuts could have a detrimental effect.   
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9.2 Future studies 
It is still unclear how PNA interaction with the cell surface glycoproteins 
MCAM and PECAM induces endothelial cytokine secretion. Further investigation 
of their interaction, for example the carbohydrate structure that PNA interacts 
with on MCAM and PECAM, is needed. In vivo studies of the effect of PNA-induced 
cytokine secretion on metastasis will also be needed to further validate the PNA 
actions for future potential diet recommendation to patients. Plant lectins similar 
to PNA with the same carbohydrate recognition domains, will also be studied for 
their roles in cancer metastasis. Observation studies such as cohort studies on the 
relationship between nut consumption and the prognosis of colorectal cancer or 
lung cancer are also suggested.  
More broadly, this study suggests an impact of dietary lectin PNA on cancer 
metastasis which is a largely unexplored area in cancer research. It is possible that 
other dietary lectins may also have direct or indirect influence on tumour 
spreading hence affect the overall survival of patients. This is an area that deserves 
more attention and research in future.  
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Appendix 1 
The human cytokine array was purchased from the R&D systems. (Catalog Number ARY005) 
 
Coordinate Target/Control Alternate 
Nomenclature 
A1,A2 Reference Spot ______ 
A3,A4 C5/C5a Complement 
Component 5/5a 
A5,A6 CD40 ligand CD154 
A7,A8 G-CSF CSFβ,CSF-3 
A9,A10 GM-CSF CSFα,CSF-2 
A11,A12 GROα CSCL1 
A12,A13 I-309 CCL1 
A13,A14 sICAM-1 CD54 
A15,A16 IFN-γ Type II IFN 
A17,A18 Reference Spot ______ 
A19,A20 IL-1α IL-1F1 
B3,B4 IL-1β IL-1F2 
B5,B6 IL-1ra IL-1F3 
B7,B8 IL-2 ______ 
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B9,B10 IL-4 ______ 
B11,B12 IL-5 ______ 
B13,B14 IL-6 ______ 
B15,B16 IL-8 CXCL8 
B17,B18 IL-10 ______ 
C3,C4 IL-12 p70 ______ 
C5,C6 IL-13 ______ 
C7,C8 IL-16 LCF 
C9,C10 IL-17 ______ 
C11,C12 IL-17E ______ 
C13,C14 IL-23 ______ 
C15,C16 IL-27 ______ 
C17,C18 IL-32α ______ 
D3,D4 IP-10 CXCL10 
D5,D6 I-TAC CXCL11 
D7,D8 MCP-1 CCL2 
D9,D10 MIF GIF, DER6 
D11,D12 MIP-1α CCL3 
D13,D14 MIP-1β CCL4 
D15,D16 Serpin E1 PAI-1 
D17,D18 Reference Spot ______ 
E1,E2 RANTES CCL5 
E3,E4 SDF-1 CXCL12 
E5,E6 TNF-α TNFSF1A 
E7,E8 sTREM-1 ______ 
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E9,E10 Negative Control ______ 
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Appendix 2 
The human phospho-kinase array was purchased from the R&D systems. (Catalog Number 
ARY003B) 
Membrane/Coordinate Target/Control  Phosphorylation Site 
A-A1, A2 Reference Spot  ___ 
A-A3, A4 p38α T180/Y182 
A-A5, A6 ERK1/2  T202/Y204,Y187 
A-A7, A8 JNK 1/2/3  T183/Y185,Y223 
A-A9, A10 GSK-3α/β  S21/S9 
B-A13, A14 p53 S392 
B-A17, A18 Reference Spot  ___ 
A-B3, B4 EGF R Y1086 
A-B5, B6 MSK1/2  S376/S360 
A-B7, B8 AMPKα1 T183 
A-B9, B10 Akt 1/2/3 S473 
B-B11, B12 Akt 1/2/3 T308 
B-B13, B14 p53 S46 
A-C1, C2 TOR S2448 
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A-C3, C4 CREB S133 
A-C5, C6 HSP27 S78/S82 
A-C7, C8 AMPKα2 T172 
A-C9, C10 β-Catenin ___ 
B-C11, C12 p70 S6 Kinase T389 
B-C13, C14 p53 S15 
B-C15, C16 c-Jun S63 
A-D1, D2 Src Y419 
A-D3, D4 Lyn Y397 
A-D5, D6 Lck Y394 
A-D7, D8 STAT2 Y689 
A-D9, D10 STAT5a Y694 
B-D11, D12 p70 S6 Kinase T421/S424 
B-D13, D14 RSK1/2/3 S380/S386/S377 
B-D15, D16 eNOS S1177 
A-E1, E2 Fyn Y420 
A-E3, E4 Yes Y426 
A-E5, E6 Fgr Y412 
A-E7, E8 STAT6 Y641 
A-E9, E10 STAT5b Y699 
B-E11, E12 STAT3 Y705 
B-E13, E14 p27 T198 
B-E15, E16 PLC-γ1 Y783 
A-F1, F2 Hck Y411 
A-F3, F4 Chk-2 T68 
A-F5, F6 FAK Y397 
A-F7, F8 PDGF Rβ Y751 
A-F9, F10 STAT5a/b Y694/Y699 
B-F11, F12 STAT3 S727 
B-F13, F14 WNK1 T60 
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B-F15, F16 PYK2 Y402 
A-G1, G2 Reference Spot ___ 
A-G3, G4 PRAS40 T246 
A-G9, G10 
PBS (Negative 
Control) ___ 
B-G11, G12 HSP60 ___ 
B-G17, G18 
PBS (Negative 
Control) ___ 
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Appendix 3 
Mass spectrometry results 
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